

Regulation of Cell Cycle Progression and Cellular Survival in Primary Rat Hepatocytes

by
Lene Wierød



UNIVERSITY OF OSLO
FACULTY OF MEDICINE

Laboratory for Toxicopathology

Institute of Pathology

Rikshospitalet Radiumhospitalet Medical Centre

2007

© Lene Wierød, 2007

*Series of dissertations submitted to the
Faculty of Medicine, University of Oslo
No. 525*

ISBN 978-82-8072-704-6

All rights reserved. No part of this publication may be reproduced or transmitted, in any form or by any means, without permission.

Cover: Inger Sandved Anfinsen.
Printed in Norway: AiT e-dit AS, Oslo, 2007.

Produced in co-operation with Unipub AS.
The thesis is produced by Unipub AS merely in connection with the thesis defence. Kindly direct all inquiries regarding the thesis to the copyright holder or the unit which grants the doctorate.

*Unipub AS is owned by
The University Foundation for Student Life (SiO)*

ACKNOWLEDGEMENT

The present work has been carried out at Laboratory for Toxicopathology, Institute of Pathology, Rikshospitalet Radiohospitalet Medical Centre, University of Oslo, during the period 2000-2006. I am grateful for the financial support from the Norwegian Research Council and from the Norwegian Cancer Society.

First, I would like to express my gratitude to Professor Henrik S. Huitfeldt, my supervisor, for accepting me into his laboratory and providing me with the opportunity to start the work that has resulted in this Ph.D. thesis. Thanks for your everlasting support and guidance.

I also want to express my gratitude to Ellen Skarpen for productive discussions of experimental data and helpful advice concerning manuscript writing.

I would further like to acknowledge present and past members of our group for their invaluable help, inspiration and friendship: Carola Rosseland, Helga Grøsvik, Morten P. Oksvold and Birgitte Lindeman.

Many thanks go to all other colleges that I have worked with along the years, and to friends and family for their help and support.

Oslo, January 2007

Lene Wierød

TABLE OF CONTENTS

ACKNOWLEDGEMENT.....	3
TABLE OF CONTENTS.....	5
ABBREVIATIONS.....	6
PUBLICATIONS INCLUDED	7
INTRODUCTION.....	9
<i>Background.....</i>	<i>9</i>
<i>Intracellular signalling.....</i>	<i>10</i>
<i>Cell-cycle progression and regulation.....</i>	<i>14</i>
Cyclin-dependent kinases and cyclins	15
CDK inhibitors	20
Nuclear translocation.....	21
<i>Cellular growth arrest</i>	<i>22</i>
p53	22
Oxidative stress.....	24
<i>Cell survival or apoptosis</i>	<i>25</i>
AIMS OF THE STUDY.....	29
METHODOLOGICAL CONSIDERATIONS	30
<i>Cell cultures.....</i>	<i>30</i>
<i>Transfection</i>	<i>31</i>
<i>Immunological methods</i>	<i>31</i>
<i>Measurement of proliferation</i>	<i>32</i>
<i>Cell death assay.....</i>	<i>33</i>
SUMMARY OF ARTICLES	34
DISCUSSION OF RESULTS.....	37
<i>p53 dependent proliferation.....</i>	<i>37</i>
<i>CDK2 regulation in G1 phase</i>	<i>39</i>
<i>ERK in survival and proliferation.....</i>	<i>42</i>
CONCLUDING REMARKS.....	46
REFERENCES.....	48

ABBREVIATIONS

CAK	Cdk-activating kinase
CDK	Cyclin-dependent kinase
CKI	Cyclin-dependent kinase inhibitors
ECM	Extracellular matrix
EGF	Epidermal growth factor
EGFR	Epidermal growth factor receptor
ERK	Extracellular signal regulated protein kinase
GDP	Guanosine diphosphate
GEF	Guanine-nucleotide exchange factor
GTP	Guanosine triphosphate
H ₂ O ₂	Hydrogen peroxide
MAPK	Mitogen-activated protein kinase
MEK	Mitogen/ERK kinase
NES	Nuclear export sequence
NLS	Nuclear localization sequence
PI3K	Phosphatidylinositol-3 kinase
PIP ₂	Phosphatidylinositol (3,4)-diphosphate
PIP ₃	Phosphatidylinositol (3,4,5)-triphosphate
PKB	Protein kinase B
Rb	Retinoblastoma protein
ROS	Reactive oxygen species
RTK	Receptor tyrosine kinase
RSK	Ribosomal S6 kinase
TGF-β	Transforming growth factor- β

PUBLICATIONS INCLUDED

- I Wierød L, Rosseland CM, Lindeman B, Oksvold MP, Grøsvik H, Skarpen E, and Huitfeldt HS. Activation of the p53-p21^{Cip1} Pathway is Required for CDK2 Activation and Proliferation in Primary Rat Hepatocytes. Submitted November 2006.
- II Wierød L, Rosseland CM, Lindeman B, Oksvold MP, Grøsvik H, Skarpen E, and Huitfeldt HS. CDK2 Regulation through PI3K and CDK4 is Necessary for Cell Cycle Progression of Primary Rat Hepatocytes. Submitted November 2006.
- III Rosseland CM, Wierød L, Oksvold MP, Werner H, Østvold AC, Thoresen GH, Paulsen RE, Huitfeldt HS, and Skarpen E (2005). Cytoplasmic Retention of Peroxide-Activated ERK Provides Survival in Primary Cultures of Rat Hepatocytes. *Hepatology*, Vol. 42, No 1, 200-207.
- IV Rosseland CM, Wierød L, Flinder LI, Oksvold MP, Skarpen E, Huitfeldt HS. Distinct Functions of H-Ras and K-Ras in Proliferation and Survival of Primary Hepatocytes Due to Selective Activation of ERK and PI3K. Submitted December 2006.

INTRODUCTION

Background

The liver is an excellent tissue for the study of growth regulation because of its ability to regenerate by a process of compensatory growth following surgical resection or toxic injury. Much of the investigation on the mechanisms of hepatic growth has been done in partially hepatectomized animals *in vivo* or in primary cultures of isolated hepatocytes. Furthermore, primary hepatocytes can be maintained in a serum-free medium with defined growth factors such as epidermal growth factor (EGF) [1, 2] and can respond to growth factor stimulation by expressing many of the same cell cycle regulatory proteins that are expressed in the liver and that drive liver regeneration *in vivo*.

Liver models are also well suited for studies of the early phases of carcinogenesis, because the growth of preneoplastic, cancer-prone lesions can be synchronously induced and are easily identifiable. Typically, carcinogen exposure results in p53 induction and growth inhibition. Initiated, preneoplastic cells are resistant to the cytotoxic effects of carcinogen exposure, compared to normal cells, and therefore escape this growth inhibition. Thereby, the cells may develop further towards neoplasia. Our laboratory has previously shown changes in the growth factor regulated phase of the cell cycle in carcinogen-exposed liver. In cultured hepatocytes, growth arrest was accompanied by altered signalling through the EGF receptor and a subsequent reduced nuclear accumulation of activated ERK [3]. Furthermore, carcinogen exposure led to delayed induction of cyclin D1 and abridged nuclear accumulation of cyclin dependent kinase 2 (CDK2) and CDK4 [4]. During these studies we decided to further explore the physiological mechanisms that regulate CDK2 and CDK4 nuclear trafficking in normal cells. The work

presented also describes growth factor- and stress activated ERK and its role in intracellular signalling.

Intracellular signalling

Hepatocytes from adult animals are constitutively resting cells, and growth factor stimulation is necessary to advance their cell cycle recruitment and progression, until they become growth factor independent just prior to DNA synthesis. EGF, TGF α and HGF are all potent liver mitogens [5]. The former two bind to and activate the plasma membrane receptor tyrosine kinase EGF receptor (EGFR). The best characterized intracellular mitogenic signal thus initiated is the Ras-Raf-MEK-MAPK pathway [6, 7] (figure 1). The interaction between ligand activated EGFR and Shc/Grb2, either through Grb2 binding alone or as a preformed Shc/Grb2 complex, results in the recruitment of Sos to the plasma membrane [8-10]. Sos operates as a guanosine triphosphate (GTP) exchange factor converting an inactive guanosine diphosphate (GDP)-bound Ras to an active GTP-bound Ras [11, 12]. Ras is a membrane-localized G-protein, functioning as molecular switches in a variety of signalling pathways, including MAPK. There are three major isoforms of classical Ras; H-Ras, K-Ras and N-Ras, sharing a high degree of sequence homology [13].

Activated Ras mediates activation of the serine/threonine kinase Raf [14, 15]. The activation of Raf is complex and the process is not yet fully understood. Raf resides in the cytosol in an inactive state in complex with heat shock proteins and 14-3-3 ζ [16]. A binding site for Raf is created on the GTP-bound Ras upon ligand activation of EGFR. When bound to the Ras effector loop at the membrane, Raf then interacts through its zinc finger domain with a second epitope on Ras, which must be prenylated [16, 17]. Raf is phosphorylated on serine and tyrosine

residues, and it is suggested that this stabilizes an open, active Raf configuration, enabling its release from Ras-GTP into the cytosol [17, 18]. Raf then phosphorylates and activates the threonine/tyrosine kinases MAPK/ERK kinase (MEK) 1 and 2 by serine phosphorylation. MEK then activates the serine/threonine kinases MAPK ERK1 and ERK2 through phosphorylation on threonine and tyrosine residues [19].




Figure 1: A schematic illustration of the MAPK pathway. Ligand-binding of Receptor Tyrosine Kinase (RTK) leads to autophosphorylation of the receptor and assembly of a signalling complex including Grb2, Sos and Ras. Activated Ras recruits Raf to the membrane. Raf then starts a cascade of phosphorylation through MEK and MAPK. Activated MAPK translocates to the nucleus where it phosphorylates a number of substrates.

CM=cellular membrane, NM=nuclear membrane.

Figure from <http://jorde-lab.genetics.utah.edu/people/reha/Reha.html>

Upon activation, ERK can translocate to the nucleus and phosphorylate substrates important for growth progression [20]. The induction of cyclin D1 mRNA has most frequently been attributed to the

activation of ERK [21]. In most cases, activation of Ras-Raf-MEK-ERK cascade induces cyclin D1 gene expression. Several studies have shown that the induction of cyclin D1 requires only moderate ERK activity, but the activity must be sustained for several hours [22]. Sustained ERK signalling in response to integrin and RTK synergism [21] may therefore explain the joint growth factor plus ECM requirement for cyclin D1 expression. However, it appears that MAPK pathway is not the only signalling pathway required for accumulation of cyclin D1 in G1-phase.

Phosphatidylinositol-3 kinase (PI3K) is another important modulator of cell survival, mitogenesis, cytoskeletal remodelling, metabolic control and vesicular trafficking in various cell systems [23]. PI3Ks are grouped into three classes (I-III) according to their substrate preference and sequence homology. Different classes of PI3K have distinct roles in cellular signal transduction, as do the different isoforms that can exist within each class. Class I PI3Ks are divided into two subfamilies, depending on the receptors to which they couple. Class 1A PI3Ks (PI3K α , β and δ) are activated by growth factor receptor-tyrosine kinases (RTKs), whereas class 1B PI3K (PI3K γ) is activated by G protein-coupled receptors. Both type 1A and type 1B PI3Ks are also activated by Ras [24]. Class 1A PI3Ks are heterodimers composed of a p110 catalytic subunit and a p85 regulatory subunit. PI3K is activated by direct interaction between the p110 subunit and GTP-bound Ras [25], or by association of the p85 subunit to activated growth factor receptors [26, 27]. In rat hepatocytes, Gab2 has been identified as a key molecule responsible for EGF-induced PI3 kinase activation [28]. Following, all class 1 PI3Ks phosphorylate phosphatidylinositol (3,4)-diphosphate (PIP₂), a constitutive membrane component, to create the lipid second messenger phosphatidylinositol (3,4,5)-triphosphate (PIP₃) (figure 2).




Figure 2: A schematic illustration of the PI3K signalling pathway. Aktivation of Receptor Tyrosine Kinase (RTK) leads to autophosphorylation on tyrosine residues and transphosphorylation of adaptor proteins with SH₂-domain. PI3K binds directly to phosphotyrosine residues on growth factor receptors or to adaptor proteins. Following activation, PI3K phosphorylates PtdIns-4,5-P₂ to create the lipid second messenger PtdIns-3,4,5-P₃ (PIP₃). PIP₃ phosphorylates PDK1. Activated PDK1 phosphorylates Akt, whereas Akt next phosphorylates a number of effector proteins, leading to complex events like cell cycle progression, survival or apoptosis. PTEN dephosphorylates PIP₃ and therefore terminates PI3K signalling.

Figure from <http://www.benbest.com/health/cancer.html>

The PIP₃ signal is mediated by its binding to the plextrin homology (PH) domain of target proteins, which induces their membrane translocation and/or conformational changes. Known PIP₃ targets are numerous and from a variety of enzyme classes, e.g. protein kinases, phospholipases and guanine-nucleotide exchange factors (GEFs). These PIP₃ targets together regulate a huge list of essential cellular functions including transcription, translation, protein synthesis,

cell survival, cell cycle entry and the structure of the actin cytoskeleton [29]. PTEN (phosphatase and tensin homologue) dephosphorylates PIP₃ and therefore terminates PI3K signalling [29].

The best known downstream target of PI3K is Akt, which transmit survival signals from growth factors [30-32]. Akt inhibits GSK3 β and FoxO transcription factors, which in turn control cell cycle regulators like cyclin D1 and p27^{Kip1}. [33-37]. Inhibition of PI3K activity blocks both cyclin D1 mRNA and protein expression [38].

Requirement for PI3K for mammalian cell cycle progression was first recognized by studies adopting platelet-derived growth factor (PDGF) receptor mutants that lack phosphoacceptor sites required for binding of PI3K p85 [39, 40], as well as “add-back” mutants with selective restoration of these sites [41]. Inhibitors of PI3K, LY294002 and wortmannin, have also been shown to inhibit S-phase entry in a variety of cell types [42-45].

Cell-cycle progression and regulation

Cell cycle progression is an exactly regulated process where the fundamental task is to ensure that DNA is faithfully replicated and that sister chromatids are correctly segregated during mitosis. To ensure this, the cell has several cell cycle checkpoints. When the cells contain DNA damages that have to be repaired, cells activate DNA damage checkpoint that arrests the cell cycle.

The periods of the cell cycle associated with DNA replication (S-phase) and mitosis (M phase) are separated by gaps of varying lengths called G1 and G2 (figure 3).

Progression of cells through the cell cycle is facilitated through the sequential activation of CDK-complexes [46, 47]. These complexes consist of a regulatory subunit (cyclin) and a catalytic subunit (CDK),

which are assembled and activated at specific points of the cell cycle. In many regards, the control of cell cycle progression by cyclins and CDKs is remarkably well conserved throughout eukaryotic species [48].




Figure 3: Regulation of the mammalian cell cycle. The periods of the cell cycle associated with DNA replication (S-phase) and mitosis (M-phase) are separated by gaps of various lengths called G1- and G2-phase. The G0 phase is a period in the cell cycle where cells exist in a quiescent state. To maintain genomic integrity, the cells are equipped with several cell cycle checkpoints (red arrows).

Figure from homepage.mac.com/enognog/checkpoint.htm.

Cyclin-dependent kinases and cyclins

Cyclin dependent kinases are the catalytic subunits of a large family of heterodimeric serine/threonine kinases whose best-characterized members are involved in controlling progression through the cell cycle (figure 4). According to the latest versions of the human and mouse genomes, there are 11 genes encoding CDKs and 9 other genes encoding CDK-like proteins [49].

Studies using sea urchin eggs identified a series of proteins that were synthesized and destroyed at each cleavage division. On the basis of this feature, these proteins were designed cyclins [50]. Analysis of the human genome has identified at least 29 genes encoding related proteins that share a conserved stretch of 150 amino acid residues termed cyclin-box. This domain is formed by five helical regions and is responsible for binding to CDKs [49]. Transcriptional control [51] and ubiquitin-mediated degradation [52] ensure the proper and irreversible timing of cyclin expression. Cyclin binding activates CDKs by inducing conformational changes in their structure [53, 54]. Cyclins have also been suggested to determine the substrate specificity of CDKs [55-58].

The G1 and S phases

Progression through G1 is regulated by a complex mechanism that can involve at least three CDKs – CDK4, CDK6 and CDK2 – and their regulators [59, 60]. Mitogenic signalling induces synthesis of the D-type cyclins and possibly the proper folding and transport of CDK4 and /or CDK6 to the nucleus. Both the PI3 kinase – and MAPK pathways are required for hepatocyte cyclin D1 induction in response to mitogens [61].

In studies of mammalian cells, a clear theme has emerged concerning the role of the D-type cyclins during G1 phase. They seem to act as intracellular “sensors” of extracellular stimuli that promote proliferation [60, 62]. However, the role of the D-type cyclins appears to vary significantly between cell types. For example, whereas cyclin D1 is a pivotal mediator of G1 progression in many cell types including hepatocytes, it does not appear to mediate proliferation in lymphocytes, in which cyclin D2 appears to perform a similar function [63, 64]. The role of cyclin D3 is highly dependent upon the cellular context. It appears to promote cell cycle progression in some cell types and growth

arrest or differentiation in others. In hepatocytes, cyclin D3 is expressed in quiescent cells and is only modestly responsive to EGF, insulin or PI3 kinase signalling, suggesting that it does not play a critical role in regulating progression through G1 phase in response to these signals [61].

Positive regulation of CDK activity occur in two steps: phosphorylation on a central threonine residue (Thr160 and Thr172 for CDK2 and CDK4, respectively) by CDK activating kinase (CAK) and dephosphorylation of the threonine (Thr14) and tyrosine (Tyr15) residues by the Cdc25 phosphatase family [65, 66].

Active complexes of CDK4 or CDK6 and D-type cyclins phosphorylate members of the retinoblastoma (Rb) protein family, which includes pRb, p107 and p130. These proteins contain multiple sites for phosphorylation by CDKs, only some of which can be recognized by the CDK4-cyclin D and/or CDK6-cylin D complexes. The Rb family members have been the only demonstrated substrates for CDK4 for many years. However, recently it has been demonstrated that Smad3, a key mediator for TGF- β antiproliferative responses, is a target for inhibitory phosphorylation by both CDK4 and CDK2 [67, 68].

Although the initial phosphorylation of Rb proteins is mediated by the CDK4–cyclin D and/or CDK6–cyclin D kinases, the irreversible inactivation of these proteins is presumed to be carried out by CDK2–cyclin E. This process is believed to render cells independent of mitogenic signals and corresponds to the restriction point [59]. The restriction point has been defined as the stage during G1 in which cells no longer require mitogenic stimuli to undergo cell division.

Progressive phosphorylation of Rb by CDK4/6-cyclin D and CDK2-cyclin E releases E2F and promotes S-phase entry [69, 70]. E2F is a transcription factor that regulates the expression of genes involved in S phase (reviewed in ref. [71]). Cyclin E itself is an E2F target gene and the cyclin E promoter contains defined E2F binding sites [72-74]. This

describes a growth factor dependent cyclin E induction in late G1 phase. Thus, as CDK2-cyclin E phosphorylates and inactivates Rb, cyclin E may reinforce its own expression through a positive feedback loop [75]. In addition to Rb, other proteins that regulate cell division are also CDK2-cyclin E substrates. NPAT/p220 is a transcription factor that controls cell cycle-dependent histone gene transcription, and phosphorylation of NPAT by CDK2-cyclin E stimulates histone mRNA synthesis [76, 77]. CDK2-cyclin E also phosphorylates p27^{Kip1}, CBP/p300 and centrosomal proteins like nucleophosmin and CP110 [78-81]. Cyclin E cooperates with CDC6 as well, and this allow prereplication complexes to form during the G1-S transition [82]. Inactivation of pRb also participates in promoting the transcription of genes that are necessary for subsequent phases of the cell cycle, including those encoding the A-type and B-type cyclins. Although A-type cyclins accumulate during S phase, synthesis of B-type cyclins is not evident until the G2-M transition. Indeed, current models propose that once CDK2 is no longer associated with cyclin E, it interacts with the newly synthesized A-type cyclins, A1 and A2. While cyclin A1 is limited to male germ cells, cyclin A2 is widely expressed [83, 84]. In cultured cells, cyclin A2 functions during both G1-S and G2-M phases [85-87]. Cyclin A2 can bind and activate CDK1 and CDK2 [88-90]. CDK2-cyclin A complexes have been reported to phosphorylate numerous proteins that are thought to be required for proper completion and exit from S phase. These proteins include upstream regulators of Cyclin A (pRb), transcription factors (E2F1, B-Myb), proteins involved in DNA replication, DNA repair, histone modification, ubiquitine-mediated proteolysis and cell cycle checkpoints (p53, p21^{Cip1}, MDM2) [60].

The G2 and M phases

At the end of S phase, A-type cyclins associate with CDK1. CDK2-cyclin A and CDK1-cyclin A complexes share several substrates and whether these complexes have differential roles during the S to G2 phase remains obscure. During G2, A-type cyclins are degraded, whereas the B-type cyclins are actively synthesized. As a consequence, CDK1 binds to B-type cyclins – an association believed to be essential for triggering mitosis [91].




Figure 4: Regulation of the mammalian cell cycle. CDK4-Cyclin D complexes, together with CDK2-cylin E complexes, regulate G1 progression. In S-phase, CDK2-cylin A complexes ensure transition to the G2 and M-phase, whereas CDK1-cyclin B complexes, in M-phase, make the cycle complete. p16 and p21 are CDK inhibitors, which also regulate cell cycle progression.

Figure adapted from www.cicr.uq.edu.au/cancerBiology/cellCycle.html

CDK activating kinase

CDK7 together with cyclin H and the assembly factor MAT1 forms the CAK complex, responsible for the activating phosphorylation of CDK1, CDK2, CDK4 and CDK6 [92-98]. CAK is located in the nucleus, mainly in coiled bodies [99, 100]. CDK7 activity is invariant during cell cycle, but levels and activity of CDK7 are both reduced in quiescent G0 cells [100, 101].

CDK inhibitors

It is generally agreed that CDK inhibitors play a critical role in regulating cell cycle progression and exit during morphogenesis and differentiation and/or in maintaining cell quiescence [60, 102, 103]. Cyclin dependent kinase inhibitors (CKIs) have been assigned to one of two families based on their structures and CDK targets. The first class includes the INK4 proteins (inhibitors of CDK4), so named for their ability to specifically inhibit the catalytic subunits of CDK4 and CDK6. Four such proteins, p16^{INK4a} [104], p15^{INK4b} [105], p18^{INK4c} [106, 107] and p19^{INK4d} [108] are composed of multiple ankyrin repeats and bind only to CDK4 and CDK6, and not to other CDKs or to D-type cyclins. The second class of inhibitors includes p21^{Cip1} [109-114], p27^{Kip1} [115-117] and p57^{Kip2} [118, 119] all of which contain characteristic motifs within their amino-terminal moieties that enable them to bind to cyclin and CDK subunits [120-125]. In hepatocytes, p21^{Cip1} is induced by growth factors during G1 phase, whereas p27 expression do not vary substantially during the cell cycle and is not dependent upon growth factors [126]. Based largely on *in vitro* experiments and *in vivo* overexpression studies, CKIs of the Cip/Kip family were initially thought to interfere with the activities of cyclin D-, E- and A-dependent kinases. More recent work has altered this view and revealed that

although the Cip/Kip proteins are potent inhibitors of cyclin E and A-dependent CDK2, they also act as positive regulators of cyclin D-dependent kinases [60, 127, 128].

Nuclear translocation

Little is known about the exact mechanisms that control nuclear import and export of cyclin-CDK complexes. CDK4-Cyclin D1 is imported into the nucleus in G1 phase, possibly by piggy-backing on the p21^{Cip1}/p27^{Kip1} CDK-inhibitors [128, 129], and is then exported in S phase concomitant with phosphorylation by GSK3 and subsequent proteolysis [130].

The CDK2 sequence does not contain a classical nuclear localization signal (NLS), but CDK2 is a small protein and may thus enter the nucleus by diffusion. However, efficient nuclear translocation of CDK2 is likely to depend on association with a carrier protein. Its regulating partner, Cyclin E, contains NLS, thus cyclin E – CDK2 complexes may translocate to the nucleus independently of p21^{Cip1} piggy-backing. Moreover, it has recently been suggested that the NLS of cyclin E is not functional [55, 131]. In addition, our studies suggest that nuclear translocation of G1 CDKs rely on p21^{Cip1} expression (submitted data).

The mechanisms responsible for promoting nuclear translocation of ERK and controlling its durability are largely unknown. In quiescent cells, ERK is located in the cytoplasm, in complex with its activator MEK [132]. Because of its nuclear export sequence, MEK localizes in the cytoplasm irrespectively of its activation state [133]. ERK itself does not contain a nuclear export sequence or a nuclear import sequence [134]. In spite of this, ERK accumulates in the nucleus following activation by a potent mitogen [20]. Nuclear export of dephosphorylated

ERK is also mediated by MEK, which shuttles in and out of the nucleus as a result of its nuclear export sequence [135].

Cellular growth arrest

Growth arrest is a reversible halt of the cell cycle that occurs at either the G1/S or G2/M barrier. Growth arrest in G1 is a conserved response to a wide spectrum of cellular stresses like oxidative damage, radiation, heat stress, DNA damage due to carcinogens etc. Deregulation of the G1 checkpoint in cancer is rather a rule than an exception [47].

p53

The p53 gene, first described in 1979, was originally believed to be an oncogene, but genetic and functional data obtained ten years after its discovery showed it to be a tumor suppressor. Just as a car's brakes regulate its speed, properly functioning tumor-suppressor genes act as brakes to the cycle of cell growth, DNA replication and division into two new cells [136].

The p53 protein is known to act biochemically as a transcription factor and biologically as a tumor suppressor. The biological functions of p53 are mainly mediated through transcriptional regulation of its downstream target genes. For example, p53-induced growth arrest is achieved primarily by transactivation of p21^{Cip1} for G1 arrest (figure 5) and of 14-3-3s for G2 arrest [137].




Figure 5: p53-mediated growth arrest in G1. Stress-activated p53 induces p21^{Cip1}. p21^{Cip1} then binds to CDK-cyclin complexes and inhibits CDK-activity, a process that leads to G1-arrest. p53 is also able to inhibit CAK directly to inhibit cell cycle progression.

Figure modified from www.eurekah.com/dbimages/blagosklonny_6_2.jpg

Among the signals that activate the p53 protein, damage to the integrity of the DNA template is the most studied. Gamma or UV irradiation, alkylation of bases, depurination of DNA or reaction with oxidative free radicals all alter the DNA in different ways, and for each damaging agent, a different detection and repair mechanism is employed by the cell [139-141]. The activation of the p53 protein in response to stresses is mediated and regulated by protein kinases, histone acetyltransferases, methylases, ubiquitin and sumo ligases. In addition, the activated p53 protein appears to interact with a number of proteins that are important for its transcriptional activity such as promyelocytic leukaemia (PML) bodies and the Werner helicase [142-144].

CAK also has a role in response to DNA damage. Two different studies showed that p53 is a substrate of CDK7 *in vitro* [145, 146]. Phosphorylation of p53 enhanced the ability of p53 to bind to the

sequence-specific p53-responsive DNA element. In addition, a direct interaction between p53 and cyclin H has been observed both *in vitro* and *in vivo*, and binding of p53 to CAK reduces CAK activity [138].

MDM2 prevents p53-dependent gene expression through diverse mechanisms. It inhibits transactivation by binding and occluding the p53 N-terminal transactivating domain, preventing the interaction of p53 with the basal transcription machinery [147-149]. Various stresses result in the acetylation of p53 by the histone acetyl transferases PCAF and p300/CBP; however, this too can be blocked by the association of p53 with MDM2 [150-154]. In addition to these direct mechanisms of transcriptional inhibition, MDM2 can indirectly inhibit p53-dependent gene expression by ubiquitinating and degrading p53 [155, 156]. MDM2 consists of several potential PI3 kinase binding sites of which Ser17 and Ser395 are phosphorylated *in vitro* and *in vivo*, respectively [157, 158]. Akt has been suggested to regulate the intracellular localization of MDM2 by phosphorylation on serines 166 and 186 [159].

Oxidative stress

Oxidative stress may be defined as an imbalance between cellular production of reactive oxygen species (ROS) and antioxidant defence mechanisms [160]. ROS are defined as partially reduced metabolites of molecular oxygen and include superoxide anion ($O_2^{\bullet-}$), hydrogen peroxide (H_2O_2) and hydroxyl radical (OH^{\bullet}). They are highly reactive, and may cause oxidative damage to cellular macromolecules [161]. H_2O_2 has a relatively long half-life and is soluble in both lipid and aqueous media, thus it easily diffuses to its cellular targets [162].

Growth factors and cytokines are capable of generating ROS that participate in cell signalling [161, 163, 164]. In agreement with this, Carmona-Cuenca et al showed that both EGF and TGF- β increased ROS

production [165]. It is well established that membrane-localized NADPH oxidase is responsible for generation of ROS triggered by receptor binding of numerous peptide growth factors such as PDGF, HGF, insulin, VEGF and TNF α triggering cell proliferation, differentiation and apoptosis [166-168]. Rac-1 GTPase is the upstream signal enzyme for NADPH oxidase dependent ROS generation [169].

In normal hepatocytes, the major source of ROS production is toxic byproducts of oxidative phosphorylation in mitochondria. In addition, detoxification of hepatotoxins in the endoplasmic reticulum or peroxisome compartments induces an endogenous production of ROS. A number of defence systems have evolved to combat the accumulation of ROS. These include various non-enzymatic molecules (e.g. glutathione, vitamins A, C and E and flavonoids) as well as enzymatic scavengers of ROS (e.g. superoxide dismutases (SOD), catalase and glutathione peroxidase). When the cellular production of ROS exceeds the antioxidant capacity of the cell, oxidative damage of lipids, proteins or DNA will occur, resulting in oxidative stress, hepatic injury and possibly cell death [170].

It has been shown that oxidative stress leads to substantial activation of ERK and that growth factor receptors play an important role in mediating this effect. Expression of inactive mutant forms of various growth factor receptors reduces activation of ERK by oxidative stress [171], while overexpression of certain normal growth factor receptors results in enhanced activation of ERK by hydrogen peroxide [172].

Cell survival or apoptosis

The balance between positive and negative signals determines the decision between life and death. An imbalance can result in diseases

linked to increased apoptosis or decreased cell survival. The extent of DNA damage and the level of different proteins contribute to the life or death decision-making process.

In hepatocytes, growth and survival signals are initiated by EGF binding and mediated through the EGF receptor/Ras/Raf/MEK/ERK signalling pathway. In addition, PI3K provides a universal survival signal largely due to its ability to activate Akt, but PI3K is also able to block ROS production from the NADPH oxidase activation, thereby promoting survival [165].

Some proteins in the cell cycle and apoptotic pathways, have dual roles following stimulation. Both p53, Ras, Akt, pRb, CDKs, cyclins and CKIs may induce cell proliferation, cell cycle arrest or cell death; the different outcomes depends on diverse variables [173].

The p53 protein is widely recognized as a “guardian of the genome” protein functioning during the cell cycle and apoptosis [174, 175]. The factors and mechanisms underlying the decision to undergo growth arrest or apoptosis in response to p53 are not fully understood. The decision is likely complex and governed by multiple factors that depend on both extrinsic and intrinsic factors that are additionally cell type-specific. p53 induced apoptosis is mediated by activation of genes involved in two major apoptotic pathways: (1) the mitochondrial pathway, with genes such as BAX, NOXA, PUMA, p53AIP1, PIGs, and APAF-1; and (2) the death receptor pathway, with genes such as KILLER/DR5, FAS and PIDD. p53 regulates these processes by transactivating genes involved in different cellular functions, but p53 also activates transcription-independent mechanisms of apoptosis [136, 174, 176, 177]. It has also been demonstrated that MAPK signalling pathways, active in transformed cells, can differentially regulate the cellular response to p53 activation and suggest that the Ras/MEK pathway may be a specific determinant of the decision to undergo p53-dependent apoptosis or G1 arrest [137].

The anti-apoptotic effects of Ras can be mediated by up-regulation of Bcl-2 and other anti-apoptotic members of the Bcl-2 family [178]. Downstream of Ras, activated Raf, MEK and ERK contribute to the inhibition of apoptosis by phosphorylating and inactivating Bad. Activation of PI3K by Ras also inhibits apoptosis by activating Akt, which also results in phosphorylation and inactivation of Bad [179]. Akt also phosphorylates and inactivates caspase-9 [180]. However, Akt can also affect cell survival by exerting its effect on the transcription factor NF- κ B via phosphorylation of the NF- κ B regulator I κ B [181].

pRb inhibits cell cycle progression by interacting with transcription factors such as E2F. In addition pRb has been shown to suppress apoptosis. For instance, pRb-deficient embryos show defects in fetal liver haematopoiesis, neurogenesis and lens development, and extensive apoptosis was observed in these tissues [182, 183]. The mechanisms by which pRb/E2F influences apoptosis remain unknown, but E2F has been shown to induce the expression of the pro-apoptotic factor Apaf-1 and evidence suggests a role for E2F in apoptosis following DNA damage [184, 185]. E2F cannot induce apoptosis when pRb is coexpressed and pRb possibly has an anti-apoptotic effect through the inhibition of E2F [186, 187].

The role of CDKs and cyclins in cell proliferation is widely known, but contradictory results exist about the role of CDKs in apoptosis. Some studies report a pro-apoptotic activity for CDKs; they show requirement of activated CDKs during apoptosis of thymocytes [188, 189]. In addition, CDKs seem to be required for neuronal cell death [190]. Some apoptosis-inducing agents can cause induction of CDK1 and CDK2 activity prior to cell death [191]. Dominant negative mutants of CDK1, CDK2 and CDK3 suppress apoptosis, induced by staurosporine and TNF- α [192]. Contrary, inhibition of CDK2 has been shown to protect thymocytes from apoptosis, mitochondrial changes and caspase activation [189].

CDK inhibitors have been suggested to be indirectly involved in apoptosis through regulation of CDK. Improper regulation of CDK can send conflicting signals for cell division and cell cycle arrest. p21^{Cip1} can have anti or pro-apoptotic properties, for example. Overexpression of p21^{Cip1} inhibits radiation-induced apoptosis in human colorectal carcinoma cells, while an inducible expression of p21^{Cip1} sensitizes EJ tumor cells to mitomycin C-induced apoptosis [193, 194]. p27^{Kip1} may also have both pro- and anti-apoptotic effects [195-197].

TGF- β is an important growth inhibitor and inducer of apoptosis in different cell types [198]. Apoptosis induced by TGF- β has been linked to an oxidative stress process and production of ROS [199-201]. However, ROS may also induce adaptive responses through activation of proteins that mediate the survival of cells. ERK is an essential mediator of survival signals through phosphorylation of ribosomal S6 kinase (RSK), which positively influence the transcription of pro-survival genes [202]. A role for ERK in survival after ROS exposure has been shown in both cell lines and in hepatocytes [203-207]. In line with this, we found that ROS mediated adaptive responses to environmental stress through activation of ERK, providing increased cell survival [208].

AIMS OF THE STUDY

The background for the present work was studies in our laboratory showing changes in the growth factor regulated phase of the cell cycle in carcinogen-exposed liver. In cultured hepatocytes, growth arrest was accompanied by altered signalling through the EGF receptor and a subsequent reduced nuclear accumulation of ERK. Furthermore, carcinogen exposure led to reduced induction of cyclin D1 and abridged nuclear accumulation of CDK2 and CDK4. To clarify those mechanisms, it became apparent that we needed a better characterization of growth factor regulation of the G1 phase of the cell cycle in normal hepatocytes. Thus, we defined the following aims for this project:

1. Define CDK2-cyclin E regulation of growth induction in normal cells.
2. Define p53 functions in normal cell proliferation.
3. Characterize the regulation of ERK nuclear trafficking after growth factor- or stress activation.

METHODOLOGICAL CONSIDERATIONS

Detailed descriptions of the methods are given in the respective articles (appendices I-IV). The following methodological considerations will discuss the choice of model system and methods, some of their advantages and limitations, and describe some problems encountered during the course of the experimental work performed in this thesis.

Cell cultures

Cell cycle progression of normal hepatocytes was analysed by using a well-characterized *in vitro* model of primary rat hepatocytes stimulated to proliferate by addition of EGF [209, 210]. Primary hepatocytes isolated from adult liver are recruited from a resting G0 state into G1 phase of the cell cycle during cell isolation and plating [211]. Thus, these cells are effectively synchronized before receiving a further proliferative stimulus. Hepatocyte mitogens like EGF, TGF α and HGF effectively induce DNA synthesis in this model. Greater stimulation of DNA synthesis can be achieved in cultured hepatocytes from young, rather than old rats, apparently reflecting differences in signal transduction down-stream from growth factor receptors and/or in expression of genes regulating the cell cycle [212, 213]. Although mouse hepatocytes have the capacity to proliferate in the absence of growth factors in medium, proliferation activity of rat hepatocytes is tightly dependent on stimulation with mitogens. Thus, rat hepatocytes in culture represent a more appropriate model to study mitogen-dependent entry and progression along the cell cycle. However, under these conditions, the cells have limited lifespan *in vitro* (5-7 days) and usually die after one round of the cell cycle. The quality of the final suspension was checked by trypan blue exclusion as an indication of viability, and cell preparations with viability of 60-100 % were used.

Transfection

Primary hepatocytes are not easy to transfect. Thus, we tried several methods and transfection reagents to find an efficient and reproducible DNA-mediated gene transfer that did not interfere with the biological processes of interest. Viral transfection, calcium-phosphate and Lipofectamin, Transmessenger and DOTAP were evaluated considering transfection efficiency, toxicity and influence on proliferation. DOTAP, which is a special reagent for primary cells, showed highest transfection efficiency (30-60 %) and had little side effects and was therefore used in articles I, II and IV.

To quantify transfection efficiency, a PEYFP-Mem Vector, which is a fusion protein consisting of the N-terminal 20 amino acids of neuromodulin and a yellow-green fluorescent variant of the enhanced green fluorescent protein (EGFP), was detected by fluorescence microscopy in viable cells. In some experiments it seemed like the majority of the cells were transfected. This might indicate that many cells express low levels of transfected genes. However, transfection efficiencies might be underestimated because of the high autofluorescence of hepatocytes.

Immunological methods

The high specificity of immunological methods makes them useful tools in cell biology. These methods are based on recognition between antigen epitope and antibody and were used to study relative protein levels, protein phosphorylation and cellular protein localization. The specificity of the antibodies used is very important for the reliability of the results.

Western blotting was used to study protein levels and phosphorylation status. Protein dephosphorylation can happen fast. To inhibit dephosphorylation, lysis buffers contained inhibitors of

dephosphorylation in addition to inhibitors of protein degradation. When phosphorylation was examined, the samples were not stored, but immediately subjected to SDS-PAGE.

We made use of nuclear fractionation and immunofluorescence microscopy studies to characterize the cellular localization of the various proteins. One of the major concerns with immunofluorescence microscopy is antibody cross-reactions. Immunological multi-staining requires crossover controls to ensure absence of immunological cross-reactions. Nonspecific binding of antibodies cannot be totally eliminated, but it can be limited by preincubation of cells in blocking solution, antibody preabsorption and sufficient dilution of the antibody. The inherent possibilities of antibody cross-reactions, which in many cases are difficult to control for, underscores the need to supplement immunofluorescence microscopy with other techniques. We have therefore applied several different immunological methods to support our microscopy results. All antibodies used in immunofluorescence microscopy were tested by Western immunoblotting.

Co-localization of proteins detected by confocal microscopy is only indicative of distribution to identical subcellular compartment and possible direct interaction. To avoid bleed-through from the two fluorochromes used in dual staining, the images were taken sequentially. By merging the red fluorochrome image with the green fluorochrome image, possible colocalization of the proteins are visualized as yellow signals.

Measurement of proliferation

Primary hepatocytes can be maintained in a serum-free medium with defined growth factors, such as EGF, and respond to stimulation by expressing many of the same cell cycle regulatory proteins that are expressed in the liver and drives liver regeneration *in vivo*. To determine

the EGF dependent proliferation, we measured the incorporation of ^3H -thymidine into DNA by a liquid scintillation counter. ^3H -thymidine incorporated gives an accumulated measurement of the amount of cells in S-phase. To discriminate whether reduced thymidine incorporation was due to reduced proliferation or cell death, we used CPM per milligram protein as a measurement of proliferation.

^3H -thymidine incorporation is frequently used to measure hepatocyte proliferation, since the cells have a short lifetime in culture and are not viable throughout the mitosis. An alternative method might be flow cytometry, but this is difficult due to the high autofluorescence of hepatocytes.

Cell death assay

Survival mechanisms in hepatocytes exposed to H_2O_2 (article III) and TGF- β (article IV) was determined by trypan blue exclusion assay in the first article and caspase assay in the latter. In necrosis, bleb rupture and breakdown of the plasma membrane permeability barrier leads to uptake of dyes like trypan blue that enters and label nuclei of nonviable cells. One of the major concerns with this method is that dead cells lose their adhesion capacity and might be washed away before counting. This can lead to a false high viability.

In the caspase assay, cleavage of the fluorescent caspase-3 substrate Ac-DEVD-amc was measured. Caspase-3 mediates apoptotic cell-death, thus this method might also give a false high viability since it does not detect caspase-independent cell death.

SUMMARY OF ARTICLES

Article I

Activation of the p53-p21^{Cip1} Pathway is Required for CDK2 Activation and Proliferation in Primary Rat Hepatocytes.

In this study we found that p53 and p21^{Cip1} were sequentially induced by EGF in primary rat hepatocytes, and that both proteins were regulated through PI3 kinase. p53 inactivation, by transfection with a dominant negative mutant resulted in inhibited CDK2- and CDK4 nuclear accumulation, CDK activation and cell proliferation. These negative effects were neutralized by ectopic expression of p21^{Cip1}. Thus, we demonstrated that EGF-induced p53-p21^{Cip1} was important for activation of both CDK2 and CDK4 and for proliferation in primary hepatocytes.

Article II

CDK2 Regulation through PI3K and CDK4 is Necessary for Cell Cycle Progression of Primary Rat Hepatocytes.

The aim of this work was to clarify the molecular mechanisms involved in mitogen regulation of CDK2 in primary rat hepatocytes. We used two methods to knock out the CDK4 kinase activity in our cells. Indirectly, by inhibiting the PI3 kinase activity, and thus cyclin D1 induction, and directly by overexpressing a kinase-defective mutant of CDK4. We found that cyclin E was induced in hepatocyte cultures independently of growth factor stimulation and PI3K signalling, but this was not sufficient for CDK2 nuclear translocation and pRb-phosphorylation. We also demonstrated that CDK4 activity was essential

for CDK2 activation and for hepatocyte proliferation. In addition, our results suggested that PI3 kinase was involved in regulating CDK4 activity, independently of cyclin D1 induction. These results are consistent with the hypothesis that contribution of CDK2-cyclin E complexes to pRb phosphorylation requires prior action by CDK4-cyclin D1 complexes.

Article III

Cytoplasmic Retention of Peroxide-Activated ERK Provides Survival in Primary Cultures of Rat Hepatocytes.

In this study we describe a role for cytoplasmically retained, redox-activated ERK in survival during oxidative stress in primary hepatocytes. We showed that H₂O₂ induced a dose-dependent activation of ERK that was transient but equally intense as phosphorylation induced by the growth factor EGF, both being MEK-dependent. However, whereas EGF-induced phosphorylated ERK accumulated in the nucleus and induced proliferation, H₂O₂-activated ERK was arrested in the cytoplasm and had no impact on cell proliferation. Instead, inhibition of H₂O₂-induced ERK activation with the MEK inhibitor U0126 reduced cell survival during ROS exposure significantly. Also, the cytoplasmic ERK substrate RSK, a known pro-survival protein, was activated and translocated to nucleus in H₂O₂-exposed hepatocytes.

Article IV

Distinct Functions of H-Ras and K-Ras in Proliferation and Survival of Primary Hepatocytes Due to Selective Activation of ERK and PI3K

In this study we showed that the isoforms H-Ras and K-Ras differentially activated the downstream effectors ERK and PI3K, thereby having distinct implications on proliferation and survival of primary hepatocytes. We observed that transient transfection of constitutive active H-Ras as well as constitutive active K-Ras, significantly reduced TGF- β 1-mediated apoptosis in primary hepatocytes. However, whereas H-Ras mediated survival through activation of ERK and PI3K, K-Ras induced survival relied on PI3K only. Also, H-Ras but not K-Ras mediated activation of the survival protein RSK, which is a known substrate of ERK. Further, transient transfection of constitutive active H-Ras, but not K-Ras, potentiated EGF- induced proliferation and expression of dominant negative H-Ras, but not K-Ras reduced ERK phosphorylation and excluded ERK from the nucleus following EGF.

DISCUSSION OF RESULTS

Our group has previously studied growth inhibition during early carcinogenesis, and our main focus has been to determine how this contributes to cancer development. In hepatocytes, DNA-damaging carcinogen exposure led to an extensive p53 induction and growth inhibition. However, p21^{Cip1} induction, which could have explained the growth inhibition, was not observed in cell cultures, and p21^{Cip1} was not found in complex with CDK2 in an *in vivo*, carcinogen-inhibited liver regeneration model [4, 214]. Instead, cytoplasmic retention of CDK2 and CDK4 appeared to be a central mechanism related to growth inhibition. Furthermore, previous studies indicated that EGFR-ERK1/2 signalling was altered in carcinogen-exposed hepatocytes [3], which possibly could explain the alterations in CDK2 and CDK4 regulation. Since our findings could not easily be explained by current concepts of hepatocyte growth regulations, we decided to further characterize growth factor regulation of CDK2, CDK4 and p53 in normal, proliferating hepatocytes.

p53 dependent proliferation

Generally, the major role of p53 is to induce cell cycle arrest, DNA repair or apoptosis in response to cellular stress, particularly DNA damage [139]. However, new evidences support the concept that p53 might play key roles in extracellular matrix homeostasis and inflammation [215]. In addition, Inoue and coworkers have suggested that p53 is HGF regulated and indispensable for induction of hepatocyte proliferation [216].

Our studies of growth factor-induced cell cycle progression demonstrated an EGF-dependent induction of p53 and p21^{Cip1} in

hepatocytes. In line with previous data in other cell types [217], p53-p21^{Cip1} induction was a sequential event (article I).

Previous studies have shown that PI3K regulates p53-Mdm2 pathway on multiple levels under stress, induced by UV-radiation and proteasome dysfunction [218]. Recently, Bar and coworkers demonstrated that induction of p53 by Cisplatin in cultured cells required the presence of serum factors. In addition, the induction of p53 was blocked by the PI3K inhibitor LY294002, implicating the PI3K pathway as a critical mediator of the positive role of serum factors in p53 activation [219]. Also in cultured hepatocytes, we found growth factor induction of p53 to be regulated through PI3K.

When p53 was inactivated, by transfection with a dominant negative mutant or by the p53 inhibitor pifithrin- α , hepatocyte proliferation was significantly reduced. This was in accordance with studies from Inoue et al. and implicated that growth factor induced p53 was critical for cell cycle progression in hepatocytes [216].

Our observation that CDK2- and CDK4 nuclear accumulation and kinase activation was abolished when p53 was inhibited may explain why these cells did not proliferate. It is generally accepted that these two CDKs have to be transported to the nucleus to be activated and to inactivate pRb for further cell cycle progression [46, 220]. The mechanism behind nuclear transport of G1 CDK-cyclin complexes is not well understood, but piggy-backing on p21^{Cip1} has been suggested [128, 129, 221]. Since hepatocytes with an inactive p53 did not express p21^{Cip1}, wild type p21^{Cip1} was ectopically expressed in these cells. This coexpression almost completely abolished the negative effects of p53 inactivation. Thus, our results demonstrated that p53 was involved in regulating CDK2- and CDK4 activity through p21^{Cip1} expression, initiated by an EGF induced PI3 kinase activity. Furthermore, the results showed that p21^{Cip1} was necessary for nuclear translocation of CDK2 and CDK4, confirming its role as a piggy-backing nuclear transporter.

CDK2 regulation in G1 phase

In carcinogen exposed hepatocytes, reduced induction of cyclin D1 and abridged nuclear accumulation of CDK2 and CDK4 was observed [4]. Based on these findings and our observations in article I, we decided to further explore the physiological mechanisms that regulate CDK2 and CDK4 nuclear trafficking in normal cells.

During G1 phase in most experimental systems, the D- and E-type cyclins are induced and bind to their respective CDK partners to form active pRb kinases [222, 223]. In many cell types, cyclin D1 is the first cyclin to be up-regulated by growth factors during G1 phase. In hepatocytes, it has been reported that cyclin D1 induction corresponded in time with passage through the restriction point [126, 224, 225]. Previous studies have suggested that cyclin D1 plays an important role in hepatocyte proliferation [1, 38, 126, 225-228]. In accordance with Rickheim and coworkers we found that PI3K activation was required for hepatocyte cyclin D1 expression in response to mitogens [61]. On the other hand, cyclin E expression was detectable in the absence of growth factor, and its induction was not dependent upon an active PI3K (article II). In line with previous studies, we observed three cyclin E isoforms, and the two lower forms were up-regulated after EGF-stimulation [126].

Since PI3K inhibition abolished cyclin D1 induction, we expected CDK4 to be retained in the cytoplasm, even after EGF-stimulation. Our observations that both CDK4 and CDK2 was retained in the cytoplasm, implicated that mitogen-induced CDK2 nuclear translocation was dependent on an active PI3K. If this effect was mediated through CDK4 activity or not was explored by overexpression of a dominant negative mutant of the protein. Mutant CDK4^{N158} contains an Asp-to-Asn mutation at amino acid residue 158, a position conserved in all cyclin dependent kinases. This residue is involved in the binding of Mg²⁺-ATP, a necessary step for enzymatic activity of these kinases. It has been demonstrated in both insect cells and Rb^{-/-} 3T3-cells that CDK4-

inactivation lead to delayed cell cycle entry after serum starvation [229, 230]. One way to verify that CDK4 activity is inhibited might be Western blotting with a Thr172-phospho-specific antibody. Such an antibody has been used in a recent study [231], but this was just a test preparation which is currently not commercial. Thus, inhibition of CDK4 activity was confirmed by showing reduced pRb phosphorylation at a CDK4-specific site (Thr826). In hepatocytes with an inactive CDK4 kinase, we also demonstrated reduced Thr160-phosphorylation of CDK2 and reduced pRb phosphorylation at a CDK2-specific site (Ser807/811). This was confirmed by data which showed that after CDK4 inactivation, the CDK2-cyclin E complex was retained in the cytoplasm. Correspondingly, we also found proliferation of these cells to be significantly reduced. It is generally accepted that both CAK and pRb are located in the nucleus, thus if CDK2 is retained in the cytoplasm, it can neither be activated by CAK nor function as a pRb kinase. From our observations in cells with an inactive CDK4, we then demonstrated that CDK2 nuclear accumulation and CDK2 kinase activity are dependent on a prior CDK4 activity.

Lately, it has been an ongoing discussion whether mammalian cells need both CDK2 and CDK4 kinase activity for induction of S-phase [232-238]. Other CDKs may compensate for the ablation of a particular cyclin-CDK complex in the context of knock-out mice. Whether this can occur if CDKs are knocked out after cellular differentiation remains unexplored. In cultured cells, it has been suggested that phosphorylation of pRb by CDK4-cyclin D1 initiates a subsequent round of phosphorylation of the tumor suppressor which is completed by CDK2-cyclin E in late G1 phase [239, 240]. This is in accordance with our data and suggests that CDK4 and CDK2 do not have overlapping functions in differentiated hepatocytes.

Because cyclin D1 is up-regulated in many human malignancies, the response to its overexpression has been studied extensively in cell

culture systems. In general, cyclin D1 alone does not promote cell cycle progression in the absence of mitogen, but it shortens the duration of G1 phase in response to growth factors [60]. However, Nelson and coworkers have demonstrated that transient expression of cyclin D1 was sufficient to promote hepatocyte replication and liver growth [126, 227]. Conversely, we found that ectopic cyclin D1 expression did not induce CDK4 nuclear translocation, CDK2 activation or proliferation in the absence of growth factor. EGF-stimulation through PI3K was required even in this situation. Whether these differences reflect variations between our cell culture model and liver regeneration in an intact organ, or can be attributed to the adenoviral transfection method applied in the latter, remains unresolved. Our observations indicated that in addition to cyclin D1 induction, PI3K activity was necessary for translocation of CDK4- cyclin D1 complexes to the nucleus, and that this process was a prerequisite for nuclear translocation and functional activation of CDK2.

In our p53-studies (article I), we found PI3K-dependent p21^{Cip1} expression important for CDK4 and CDK2 nuclear translocation. Therefore, we explored if overexpression of both p21^{Cip1} and cyclin D1 was sufficient for CDK nuclear translocation or to initiate proliferation in our system. Preliminary data did not show proliferation in cells cotransfected with wild type p21^{Cip1} and wild type cyclin D1 in the absence of EGF, nor could CDK4 or CDK2 nuclear accumulation be observed (unpublished results). Thus, growth factor receptor signalling seemed to have additional effects critical in hepatocyte proliferation than cyclin D1 and p21^{Cip1} induction.

Also, in the light of article I, we have cotransfected hepatocytes with wild type p21^{Cip1} and dominant negative CDK4. Preliminary data from these studies showed CDK2 nuclear accumulation and increased EGF-induced proliferation, compared to CDK4^{N158} transfected cells. Furthermore, we have lately observed reduced p53 induction in CDK4

inactivated hepatocytes. This might indicate that the effect of CDK4 kinase activity on CDK2 is to induce p21^{Cip1}.

Considering the conclusions in article I and II and the preliminary results described above, we suggest that PI3K-dependent CDK4 activity is necessary for p53- p21^{Cip1} induction, and that p21^{Cip1} is essential for the subsequent CDK2 nuclear translocation and activation.

ERK in survival and proliferation

Our group has earlier found that ERK do not translocate to the nucleus in carcinogen-exposed hepatocytes. Thus, the mechanisms regulating ERK nuclear trafficking in normal hepatocyte proliferation and during hepatocyte stress appeared to be relevant to early carcinogenesis.

Oxidative stress by ROS may cause severe damage and cell death. However, ROS may also induce adaptive responses through activation of proteins that mediate survival of cells. Particularly, a role for ERK in survival after ROS exposure has been shown both in cell lines and in primary hepatocytes [203-207]. Whether ERK is activated in a highly regulated manner or through interference with growth regulatory pathways is still unknown. We therefore studied the potential role of ERK during adaption of hepatocytes to oxidative stress in a hydrogen peroxide environment. H₂O₂ has been suggested to act as a paracrine mediator of apoptosis and has widely been used as a model of exogenous oxidative stress. In accordance with earlier findings [203, 204], we found a strong activation of ERK during H₂O₂ exposure. We also showed that this ERK-activation was independent of an active EGFR kinase activity. Thus, H₂O₂ can activate ERK directly or via upstream activators.

MEK is the upstream activator of ERK in the signalling pathway from EGF receptor. In quiescent cells, ERK is located in the cytoplasm

where MEKs can serve as cytoplasmic anchors for ERK through direct binding interaction. Upon mitogen stimulation, the MEK-ERK association is disrupted and a proportion of ERK translocates to the nucleus [132]. Several studies show activation of MEK after ROS exposure. Also in hepatocytes, we found MEK to be the activator of ERK. However, ERK did not accumulate in the nucleus after H₂O₂ exposure, as seen after EGF stimulation. To exclude the possibility of a rapid export of the MEK/ERK complex, H₂O₂ exposed cells were pretreated with leptomycin B, a specific inhibitor of CRM1/exportin. Also in this case, ERK was exclusively located in the cytoplasm. Thus ERK activated by H₂O₂ did not enter the nucleus, but was arrested in the cytosol.

Specific intracellular localization of ERK has been shown to determine cell faith. Generally, ERK trapped in the cytoplasm blocks DNA synthesis and cell proliferation, whereas forcing an active ERK into the nucleus promotes proliferation and oncogenic transformation [241-243]. Activated ERK can provide survival through several downstream mediators, including RSK [202], which neutralizes the proapoptotic protein Bad [244]. We found a strong reduction in the survival of hepatocytes when activation of ERK was inhibited. Second, we found RSK to be activated, via ERK, by both oxidative stress and growth factor stimulation. Activated RSK was located in the nucleus. Thus, to conclude this article we hypothesized that survival in hepatocytes was mediated by redox-activated ERK from the cytoplasmic compartment through activation and nuclear transport of RSK.

Considering the results in article III, we next explored one of the upstream activators of ERK, Ras. Ras has been suggested as an upstream H₂O₂ acceptor [206]. By activating both the MAPK signalling cascade and the PI3K pathway, Ras has a role in cell proliferation as well as in inhibition and promotion of apoptosis [245].

TGF- β 1 plays an important role in mediating hepatocyte death *in vivo*, thereby controlling liver size [246]. TGF- β 1 does not activate ERK or PI3K [247], therefore we used TGF- β 1-exposure as a model to induce cell death. The apoptotic process induced by TGF- β 1 is mediated by ROS. Moreover, it includes the activation of caspases 2, 3, 7 and 8 [248]. Several growth factors, including EGF, are able to oppose the apoptotic process. In agreement with previous studies, we found that both ERK- and PI3K activation suppressed TGF- β 1-induced apoptosis [247, 249]. However, PI3K had a more potent anti-apoptotic effect on TGF- β 1-exposed primary hepatocytes.

The C-terminal portion of Ras proteins, encompassing the last 25 amino acids, is unique for each isoform and has therefore been termed the hypervariable region (HVR). The function of HVR is to mediate the association of Ras proteins with cellular membranes. This function is accomplished through post-translational modifications of HVR. Whereas H-Ras undergoes both farnesylation and palmitoylation, K-Ras undergoes only a single lipid modification – farnesylation [250]. Several studies have reported that H-Ras is retained in the endosomes to a much higher extent than K-Ras, and that the latter recycles faster to the plasma membrane due to ineffective sorting into the early endocytic compartment [251, 252]. We found endogenously expressed H-Ras and K-Ras internalized and co-localized with EGF receptor in endosome-like compartments after stimulation with EGF, suggesting an equal endosomal sorting of the two isoforms.

Recently, it has been suggested that the two homologues H-Ras and K-Ras may have different biological effect. When overexpressed in COS-cells, K-Ras has been reported to be a more potent activator of the ERK pathway, whereas H-Ras was a more potent activator of PI3K [253]. However, contradictory results have been reported, showing that oncogenic K-Ras expressed *in vivo* did not activate the Raf/ERK pathway in unstimulated cells [254]. In accordance with the latter, we

found that expression of constitutive active K-Ras (K-Ras V12) did not activate ERK in unstimulated cells. Conversely, in the absence of EGF, expression of constitutive active H-Ras led to phosphorylation, but not nuclear translocation of ERK. Still, H-Ras is critical for ERK phosphorylation and nuclear transport, since the dominant negative mutant (H-Ras N17) abolished EGF induced ERK nuclear accumulation.

To promote cell cycle progression, ERK has to be activated and translocated to the nuclear compartment [241]. However, Ras-independent pathways also need to be initiated before cells respond mitogenically to EGF [255]. This is in accordance with our findings that constitutive active H-Ras, or the combination of constitutive active H-Ras and K-Ras, were not enough to mimic growth factor stimulation and induce cell cycle progression.

Toulany and his group have shown that K-Ras mediate radio-resistance in carcinoma cell lines by activating PI3K [256]. In line with this, we found that K-Ras mediated an anti-apoptotic activity through PI3K, but not through ERK, whereas H-Ras promoted hepatocyte survival through both ERK and PI3K. Thus, according to the results in article III and IV, we suggested that redox-activated ERK promoted survival through H-Ras in primary rat hepatocytes.

CONCLUDING REMARKS

We have demonstrated that in primary rat hepatocytes, CDK4 activity was necessary for CDK2 nuclear translocation and proliferation, and that growth factor activation of p53-p21^{Cip1} was necessary for CDK4 and CDK2 trafficking. Our results were in accordance with the notion that in cells without DNA damage, p53-p21^{Cip1} activation is a positive regulator of physiological cellular proliferation. In addition to regulation of cyclin D1, PI3K controlled proliferation through p53 induction. It also appeared that an additional growth factor signalling pathway was necessary, since ectopic expression of cyclin D1 and p21^{Cip1} was not sufficient for growth induction.

Cytoplasmic retention of activated ERK remains a putative mechanism of carcinogen-induced growth inhibition and thus cell cycle progression. Although this was observed following both H₂O₂ and carcinogen (2-acetylaminofluorene) exposure, the former appeared to affect ERK differently, since it phosphorylated ERK by itself. From the cytoplasmic compartment, redox-activated ERK was able to mediate survival. Such signalling may possibly contribute to the carcinogenic development. Our results demonstrated that hepatocyte proliferation was H-Ras dependent, since K-Ras did not activate ERK. In addition, H-Ras promoted survival through both ERK and PI3K, whereas K-Ras mediated an anti-apoptotic activity through PI3K.

For further experiments, this thesis pinpoints the following problems to be addressed:

- Characterize the unknown signals, which are critical for hepatocyte cell cycle progression, in addition to cyclin D1 and p21^{Cip1} induction.

- Characterize if ectopically expressed p21^{Cip1} can recover the growth arrest in carcinogen-exposed hepatocytes.
- Characterize the upstream activator of MEK following H₂O₂-exposure.

REFERENCES

1. Hansen, L.K. and J.H. Albrecht, *Regulation of the hepatocyte cell cycle by type I collagen matrix: role of cyclin D1*. J Cell Sci, 1999. **112** (Pt 17): p. 2971-81.
2. Hansen, L.K., et al., *Integrin binding and cell spreading on extracellular matrix act at different points in the cell cycle to promote hepatocyte growth*. Mol Biol Cell, 1994. **5**(9): p. 967-75.
3. Skarpen, E., et al., *Impaired nuclear accumulation and shortened phosphorylation of ERK after growth factor stimulation in cultured hepatocytes from rats exposed to 2-acetylaminofluorene*. Mol Carcinog, 2000. **28**(2): p. 84-96.
4. Lindeman, B., et al., *The carcinogen 2-acetylaminofluorene inhibits activation and nuclear accumulation of cyclin-dependent kinase 2 in growth-induced rat liver*. Mol Carcinog, 2000. **27**(3): p. 190-9.
5. Fausto, N., A.D. Laird, and E.M. Webber, *Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration*. Faseb J, 1995. **9**(15): p. 1527-36.
6. Avruch, J., X.F. Zhang, and J.M. Kyriakis, *Raf meets Ras: completing the framework of a signal transduction pathway*. Trends Biochem Sci, 1994. **19**(7): p. 279-83.
7. Schlessinger, J., *How receptor tyrosine kinases activate Ras*. Trends Biochem Sci, 1993. **18**(8): p. 273-5.
8. Buday, L. and J. Downward, *Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor*. Cell, 1993. **73**(3): p. 611-20.
9. Li, N., et al., *Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling*. Nature, 1993. **363**(6424): p. 85-8.
10. Rozakis-Adcock, M., et al., *The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1*. Nature, 1993. **363**(6424): p. 83-5.
11. Bonfini, L., et al., *The Son of sevenless gene product: a putative activator of Ras*. Science, 1992. **255**(5044): p. 603-6.
12. Chardin, P., et al., *Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2*. Science, 1993. **260**(5112): p. 1338-43.
13. Reuther, G.W. and C.J. Der, *The Ras branch of small GTPases: Ras family members don't fall far from the tree*. Curr Opin Cell Biol, 2000. **12**(2): p. 157-65.
14. Kyriakis, J.M., et al., *Raf-1 activates MAP kinase-kinase*. Nature, 1992. **358**(6385): p. 417-21.
15. Zhang, X.F., et al., *Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1*. Nature, 1993. **364**(6435): p. 308-13.
16. Luo, Z., et al., *Oligomerization activates c-Raf-1 through a Ras-dependent mechanism*. Nature, 1996. **383**(6596): p. 181-5.
17. Avruch, J., et al., *Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade*. Recent Prog Horm Res, 2001. **56**: p. 127-55.

18. Tzivion, G., Z. Luo, and J. Avruch, *A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity*. Nature, 1998. **394**(6688): p. 88-92.
19. Payne, D.M., et al., *Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase)*. Embo J, 1991. **10**(4): p. 885-92.
20. Lenormand, P., et al., *Growth factors induce nuclear translocation of MAP kinases (p42mapk and p44mapk) but not of their activator MAP kinase kinase (p45mapkk) in fibroblasts*. J Cell Biol, 1993. **122**(5): p. 1079-88.
21. Roovers, K. and R.K. Assoian, *Integrating the MAP kinase signal into the G1 phase cell cycle machinery*. Bioessays, 2000. **22**(9): p. 818-26.
22. Weber, J.D., et al., *Ras-stimulated extracellular signal-related kinase 1 and RhoA activities coordinate platelet-derived growth factor-induced G1 progression through the independent regulation of cyclin D1 and p27*. J Biol Chem, 1997. **272**(52): p. 32966-71.
23. Fruman, D.A., R.E. Meyers, and L.C. Cantley, *Phosphoinositide kinases*. Annu Rev Biochem, 1998. **67**: p. 481-507.
24. Jimenez, C., et al., *The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras*. J Biol Chem, 2002. **277**(44): p. 41556-62.
25. Rodriguez-Viciana, P., et al., *Phosphatidylinositol-3-OH kinase as a direct target of Ras*. Nature, 1994. **370**(6490): p. 527-32.
26. Bjorge, J.D., et al., *Activated type I phosphatidylinositol kinase is associated with the epidermal growth factor (EGF) receptor following EGF stimulation*. Proc Natl Acad Sci U S A, 1990. **87**(10): p. 3816-20.
27. Rottapel, R., et al., *Substrate specificities and identification of a putative binding site for PI3K in the carboxy tail of the murine Flt3 receptor tyrosine kinase*. Oncogene, 1994. **9**(6): p. 1755-65.
28. Kong, M., et al., *Epidermal growth factor-induced phosphatidylinositol 3-kinase activation and DNA synthesis. Identification of Grb2-associated binder 2 as the major mediator in rat hepatocytes*. J Biol Chem, 2000. **275**(46): p. 36035-42.
29. Cantley, L.C., *The phosphoinositide 3-kinase pathway*. Science, 2002. **296**(5573): p. 1655-7.
30. Chan, T.O., S.E. Rittenhouse, and P.N. Tsichlis, *AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation*. Annu Rev Biochem, 1999. **68**: p. 965-1014.
31. Duronio, V., M.P. Scheid, and S. Ettinger, *Downstream signalling events regulated by phosphatidylinositol 3-kinase activity*. Cell Signal, 1998. **10**(4): p. 233-9.
32. Kandel, E.S. and N. Hay, *The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB*. Exp Cell Res, 1999. **253**(1): p. 210-29.
33. Alvarez, B., et al., *Forkhead transcription factors contribute to execution of the mitotic programme in mammals*. Nature, 2001. **413**(6857): p. 744-7.
34. Martinez-Gac, L., et al., *Control of cyclin G2 mRNA expression by forkhead transcription factors: novel mechanism for cell cycle control by phosphoinositide 3-kinase and forkhead*. Mol Cell Biol, 2004. **24**(5): p. 2181-9.

35. Medema, R.H., et al., *AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1*. Nature, 2000. **404**(6779): p. 782-7.
36. Shin, I., et al., *PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization*. Nat Med, 2002. **8**(10): p. 1145-52.
37. van Weeren, P.C., et al., *Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization of dominant-negative mutant of PKB*. J Biol Chem, 1998. **273**(21): p. 13150-6.
38. Coutant, A., et al., *PI3K-FRAP/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK supports both proliferation and survival*. Hepatology, 2002. **36**(5): p. 1079-88.
39. Coughlin, S.R., J.A. Escobedo, and L.T. Williams, *Role of phosphatidylinositol kinase in PDGF receptor signal transduction*. Science, 1989. **243**(4895): p. 1191-4.
40. Fantl, W.J., et al., *Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways*. Cell, 1992. **69**(3): p. 413-23.
41. Valius, M. and A. Kazlauskas, *Phospholipase C-gamma 1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal*. Cell, 1993. **73**(2): p. 321-34.
42. Cheatham, B., et al., *Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation*. Mol Cell Biol, 1994. **14**(7): p. 4902-11.
43. Hu, Z.W., et al., *Alpha1 adrenergic receptors activate phosphatidylinositol 3-kinase in human vascular smooth muscle cells. Role in mitogenesis*. J Biol Chem, 1996. **271**(15): p. 8977-82.
44. Vemuri, G.S. and S.E. Rittenhouse, *Wortmannin inhibits serum-induced activation of phosphoinositide 3-kinase and proliferation of CHRF-288 cells*. Biochem Biophys Res Commun, 1994. **202**(3): p. 1619-23.
45. Vlahos, C.J., et al., *A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)*. J Biol Chem, 1994. **269**(7): p. 5241-8.
46. Sherr, C.J., *G1 phase progression: cycling on cue*. Cell, 1994. **79**(4): p. 551-5.
47. Sherr, C.J., *Cancer cell cycles*. Science, 1996. **274**(5293): p. 1672-7.
48. Blow, J.J., *Editorial overview*. Curr Opin Cell Biol, 2000. **12**(6): p. 655-7.
49. Malumbres, M. and M. Barbacid, *Mammalian cyclin-dependent kinases*. Trends Biochem Sci, 2005. **30**(11): p. 630-41.
50. Evans, T., et al., *Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division*. Cell, 1983. **33**(2): p. 389-96.
51. Koch, C. and K. Nasmyth, *Cell cycle regulated transcription in yeast*. Curr Opin Cell Biol, 1994. **6**(3): p. 451-9.
52. King, R.W., et al., *How proteolysis drives the cell cycle*. Science, 1996. **274**(5293): p. 1652-9.
53. Jeffrey, P.D., et al., *Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex*. Nature, 1995. **376**(6538): p. 313-20.

54. Pavletich, N.P., *Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors.* J Mol Biol, 1999. **287**(5): p. 821-8.
55. Kelly, B.L., K.G. Wolfe, and J.M. Roberts, *Identification of a substrate-targeting domain in cyclin E necessary for phosphorylation of the retinoblastoma protein.* Proc Natl Acad Sci U S A, 1998. **95**(5): p. 2535-40.
56. Peeper, D.S., et al., *A- and B-type cyclins differentially modulate substrate specificity of cyclin-cdk complexes.* Embo J, 1993. **12**(5): p. 1947-54.
57. Sarcevic, B., R. Lilischkis, and R.L. Sutherland, *Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin-CDK complexes.* J Biol Chem, 1997. **272**(52): p. 33327-37.
58. Schulman, B.A., D.L. Lindstrom, and E. Harlow, *Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A.* Proc Natl Acad Sci U S A, 1998. **95**(18): p. 10453-8.
59. Malumbres, M. and M. Barbacid, *To cycle or not to cycle: a critical decision in cancer.* Nat Rev Cancer, 2001. **1**(3): p. 222-31.
60. Sherr, C.J. and J.M. Roberts, *CDK inhibitors: positive and negative regulators of G1-phase progression.* Genes Dev, 1999. **13**(12): p. 1501-12.
61. Rickheim, D.G., et al., *Differential regulation of cyclins D1 and D3 in hepatocyte proliferation.* Hepatology, 2002. **36**(1): p. 30-8.
62. Sherr, C.J., *The Pezcoller lecture: cancer cell cycles revisited.* Cancer Res, 2000. **60**(14): p. 3689-95.
63. Ajchenbaum, F., et al., *Independent regulation of human D-type cyclin gene expression during G1 phase in primary human T lymphocytes.* J Biol Chem, 1993. **268**(6): p. 4113-9.
64. Lukas, J., et al., *Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types.* Oncogene, 1995. **10**(11): p. 2125-34.
65. Morgan, D.O., *Principles of CDK regulation.* Nature, 1995. **374**(6518): p. 131-4.
66. Shuttleworth, J., *The regulation and functions of cdk7.* Prog Cell Cycle Res, 1995. **1**: p. 229-40.
67. Liu, F. and I. Matsuura, *Inhibition of Smad antiproliferative function by CDK phosphorylation.* Cell Cycle, 2005. **4**(1): p. 63-6.
68. Matsuura, I., et al., *Cyclin-dependent kinases regulate the antiproliferative function of Smads.* Nature, 2004. **430**(6996): p. 226-31.
69. Bartek, J., J. Bartkova, and J. Lukas, *The retinoblastoma protein pathway in cell cycle control and cancer.* Exp Cell Res, 1997. **237**(1): p. 1-6.
70. Sherr, C.J. and F. McCormick, *The RB and p53 pathways in cancer.* Cancer Cell, 2002. **2**(2): p. 103-12.
71. Dyson, N., *The regulation of E2F by pRB-family proteins.* Genes Dev, 1998. **12**(15): p. 2245-62.
72. Geng, Y., et al., *Rescue of cyclin D1 deficiency by knockin cyclin E.* Cell, 1999. **97**(6): p. 767-77.

73. Le Cam, L., et al., *Timing of cyclin E gene expression depends on the regulated association of a bipartite repressor element with a novel E2F complex*. *Embo J*, 1999. **18**(7): p. 1878-90.
74. Ohtani, K., J. DeGregori, and J.R. Nevins, *Regulation of the cyclin E gene by transcription factor E2F1*. *Proc Natl Acad Sci U S A*, 1995. **92**(26): p. 12146-50.
75. Lukas, J., et al., *Cyclin E-induced S phase without activation of the pRb/E2F pathway*. *Genes Dev*, 1997. **11**(11): p. 1479-92.
76. Ma, T., et al., *Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription*. *Genes Dev*, 2000. **14**(18): p. 2298-313.
77. Zhao, J., et al., *NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription*. *Genes Dev*, 2000. **14**(18): p. 2283-97.
78. Ait-Si-Ali, S., et al., *Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A*. *Nature*, 1998. **396**(6707): p. 184-6.
79. Okuda, M., et al., *Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication*. *Cell*, 2000. **103**(1): p. 127-40.
80. Tokuyama, Y., et al., *Specific phosphorylation of nucleophosmin on Thr(199) by cyclin-dependent kinase 2-cyclin E and its role in centrosome duplication*. *J Biol Chem*, 2001. **276**(24): p. 21529-37.
81. Vlach, J., et al., *Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc*. *Embo J*, 1996. **15**(23): p. 6595-604.
82. Coverley, D., H. Laman, and R.A. Laskey, *Distinct roles for cyclins E and A during DNA replication complex assembly and activation*. *Nat Cell Biol*, 2002. **4**(7): p. 523-8.
83. Handel, M.A. and J.J. Eppig, *Sexual dimorphism in the regulation of mammalian meiosis*. *Curr Top Dev Biol*, 1998. **37**: p. 333-58.
84. Wolgemuth, D.J., et al., *Genetic control of mitosis, meiosis and cellular differentiation during mammalian spermatogenesis*. *Reprod Fertil Dev*, 1995. **7**(4): p. 669-83.
85. Girard, F., et al., *Cyclin A is required for the onset of DNA replication in mammalian fibroblasts*. *Cell*, 1991. **67**(6): p. 1169-79.
86. Pagano, M., et al., *Cyclin A is required at two points in the human cell cycle*. *Embo J*, 1992. **11**(3): p. 961-71.
87. Pines, J. and T. Hunter, *The differential localization of human cyclins A and B is due to a cytoplasmic retention signal in cyclin B*. *Embo J*, 1994. **13**(16): p. 3772-81.
88. Elledge, S.J., et al., *CDK2 encodes a 33-kDa cyclin A-associated protein kinase and is expressed before CDC2 in the cell cycle*. *Proc Natl Acad Sci U S A*, 1992. **89**(7): p. 2907-11.
89. Kobayashi, H., et al., *Identification of the domains in cyclin A required for binding to, and activation of, p34cdc2 and p32cdk2 protein kinase subunits*. *Mol Biol Cell*, 1992. **3**(11): p. 1279-94.

90. Rosenblatt, J., Y. Gu, and D.O. Morgan, *Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A*. Proc Natl Acad Sci U S A, 1992. **89**(7): p. 2824-8.
91. Nigg, E.A., *Mitotic kinases as regulators of cell division and its checkpoints*. Nat Rev Mol Cell Biol, 2001. **2**(1): p. 21-32.
92. Fesquet, D., et al., *The MO15 gene encodes the catalytic subunit of a protein kinase that activates cdc2 and other cyclin-dependent kinases (CDKs) through phosphorylation of Thr161 and its homologues*. Embo J, 1993. **12**(8): p. 3111-21.
93. Fisher, R.P. and D.O. Morgan, *A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase*. Cell, 1994. **78**(4): p. 713-24.
94. Kato, J.Y., et al., *Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase*. Mol Cell Biol, 1994. **14**(4): p. 2713-21.
95. Matsuoka, M., et al., *Activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase*. Mol Cell Biol, 1994. **14**(11): p. 7265-75.
96. Poon, R.Y., et al., *The cdc2-related protein p40MO15 is the catalytic subunit of a protein kinase that can activate p33cdk2 and p34cdc2*. Embo J, 1993. **12**(8): p. 3123-32.
97. Solomon, M.J., J.W. Harper, and J. Shuttleworth, *CAK, the p34cdc2 activating kinase, contains a protein identical or closely related to p40MO15*. Embo J, 1993. **12**(8): p. 3133-42.
98. Solomon, M.J., T. Lee, and M.W. Kirschner, *Role of phosphorylation in p34cdc2 activation: identification of an activating kinase*. Mol Biol Cell, 1992. **3**(1): p. 13-27.
99. Jordan, P., C. Cunha, and M. Carmo-Fonseca, *The cdk7-cyclin H-MAT1 complex associated with TFIIF is localized in coiled bodies*. Mol Biol Cell, 1997. **8**(7): p. 1207-17.
100. Tassan, J.P., et al., *Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase)*. J Cell Biol, 1994. **127**(2): p. 467-78.
101. Garrett, S., et al., *Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop*. Mol Cell Biol, 2001. **21**(1): p. 88-99.
102. Sherr, C.J. and J.M. Roberts, *Inhibitors of mammalian G1 cyclin-dependent kinases*. Genes Dev, 1995. **9**(10): p. 1149-63.
103. Zhu, L. and A.I. Skoultchi, *Coordinating cell proliferation and differentiation*. Curr Opin Genet Dev, 2001. **11**(1): p. 91-7.
104. Serrano, M., G.J. Hannon, and D. Beach, *A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4*. Nature, 1993. **366**(6456): p. 704-7.
105. Hannon, G.J. and D. Beach, *p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest*. Nature, 1994. **371**(6494): p. 257-61.
106. Guan, K.L., et al., *Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function*. Genes Dev, 1994. **8**(24): p. 2939-52.

107. Hirai, H., et al., *Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6*. Mol Cell Biol, 1995. **15**(5): p. 2672-81.
108. Chan, F.K., et al., *Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4*. Mol Cell Biol, 1995. **15**(5): p. 2682-8.
109. Dulic, V., E. Lees, and S.I. Reed, *Association of human cyclin E with a periodic G1-S phase protein kinase*. Science, 1992. **257**(5078): p. 1958-61.
110. el-Deiry, W.S., et al., *WAF1, a potential mediator of p53 tumor suppression*. Cell, 1993. **75**(4): p. 817-25.
111. Gu, Y., C.W. Turck, and D.O. Morgan, *Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit*. Nature, 1993. **366**(6456): p. 707-10.
112. Harper, J.W., et al., *The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases*. Cell, 1993. **75**(4): p. 805-16.
113. Noda, A., et al., *Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen*. Exp Cell Res, 1994. **211**(1): p. 90-8.
114. Xiong, Y., et al., *p21 is a universal inhibitor of cyclin kinases*. Nature, 1993. **366**(6456): p. 701-4.
115. Polyak, K., et al., *p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest*. Genes Dev, 1994. **8**(1): p. 9-22.
116. Polyak, K., et al., *Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals*. Cell, 1994. **78**(1): p. 59-66.
117. Toyoshima, H. and T. Hunter, *p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21*. Cell, 1994. **78**(1): p. 67-74.
118. Lee, M.H., I. Reynisdottir, and J. Massague, *Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution*. Genes Dev, 1995. **9**(6): p. 639-49.
119. Matsuoka, S., et al., *p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene*. Genes Dev, 1995. **9**(6): p. 650-62.
120. Chen, J., et al., *Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA*. Nature, 1995. **374**(6520): p. 386-8.
121. Chen, J., et al., *Cyclin-binding motifs are essential for the function of p21CIP1*. Mol Cell Biol, 1996. **16**(9): p. 4673-82.
122. Lin, J., et al., *Analysis of wild-type and mutant p21WAF-1 gene activities*. Mol Cell Biol, 1996. **16**(4): p. 1786-93.
123. Nakanishi, M., et al., *Identification of the active region of the DNA synthesis inhibitory gene p21Sdi1/CIP1/WAF1*. Embo J, 1995. **14**(3): p. 555-63.
124. Russo, A.A., et al., *Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex*. Nature, 1996. **382**(6589): p. 325-31.
125. Warbrick, E., et al., *A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen*. Curr Biol, 1995. **5**(3): p. 275-82.

126. Albrecht, J.H. and L.K. Hansen, *Cyclin D1 promotes mitogen-independent cell cycle progression in hepatocytes*. Cell Growth Differ, 1999. **10**(6): p. 397-404.
127. Cheng, M., et al., *The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts*. Embo J, 1999. **18**(6): p. 1571-83.
128. LaBaer, J., et al., *New functional activities for the p21 family of CDK inhibitors*. Genes Dev, 1997. **11**(7): p. 847-62.
129. Diehl, J.A. and C.J. Sherr, *A dominant-negative cyclin D1 mutant prevents nuclear import of cyclin-dependent kinase 4 (CDK4) and its phosphorylation by CDK-activating kinase*. Mol Cell Biol, 1997. **17**(12): p. 7362-74.
130. Diehl, J.A., et al., *Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization*. Genes Dev, 1998. **12**(22): p. 3499-511.
131. Geisen, C. and T. Moroy, *The oncogenic activity of cyclin E is not confined to Cdk2 activation alone but relies on several other, distinct functions of the protein*. J Biol Chem, 2002. **277**(42): p. 39909-18.
132. Fukuda, M., Y. Gotoh, and E. Nishida, *Interaction of MAP kinase with MAP kinase kinase: its possible role in the control of nucleocytoplasmic transport of MAP kinase*. Embo J, 1997. **16**(8): p. 1901-8.
133. Fukuda, M., et al., *Cytoplasmic localization of mitogen-activated protein kinase kinase directed by its NH2-terminal, leucine-rich short amino acid sequence, which acts as a nuclear export signal*. J Biol Chem, 1996. **271**(33): p. 20024-8.
134. Cyert, M.S., *Regulation of nuclear localization during signaling*. J Biol Chem, 2001. **276**(24): p. 20805-8.
135. Adachi, M., M. Fukuda, and E. Nishida, *Nuclear export of MAP kinase (ERK) involves a MAP kinase kinase (MEK)-dependent active transport mechanism*. J Cell Biol, 2000. **148**(5): p. 849-56.
136. Vogelstein, B., D. Lane, and A.J. Levine, *Surfing the p53 network*. Nature, 2000. **408**(6810): p. 307-10.
137. Brown, L. and S. Benchimol, *The involvement of MAPK signaling pathways in determining the cellular response to p53 activation: cell cycle arrest or apoptosis*. J Biol Chem, 2006. **281**(7): p. 3832-40.
138. Schneider, E., M. Montenarh, and P. Wagner, *Regulation of CAK kinase activity by p53*. Oncogene, 1998. **17**(21): p. 2733-41.
139. Giaccia, A.J. and M.B. Kastan, *The complexity of p53 modulation: emerging patterns from divergent signals*. Genes Dev, 1998. **12**(19): p. 2973-83.
140. Gudkov, A.V. and E.A. Komarova, *The role of p53 in determining sensitivity to radiotherapy*. Nat Rev Cancer, 2003. **3**(2): p. 117-29.
141. Oren, M., *Decision making by p53: life, death and cancer*. Cell Death Differ, 2003. **10**(4): p. 431-42.
142. Blander, G., et al., *The Werner syndrome protein contributes to induction of p53 by DNA damage*. Faseb J, 2000. **14**(14): p. 2138-40.
143. Louria-Hayon, I., et al., *The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation*. J Biol Chem, 2003. **278**(35): p. 33134-41.

144. Zhu, H., L. Wu, and C.G. Maki, *MDM2 and promyelocytic leukemia antagonize each other through their direct interaction with p53*. J Biol Chem, 2003. **278**(49): p. 49286-92.
145. Ko, L.J., et al., *p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner*. Mol Cell Biol, 1997. **17**(12): p. 7220-9.
146. Lu, H., et al., *The CDK7-cycH-p36 complex of transcription factor IIIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro*. Mol Cell Biol, 1997. **17**(10): p. 5923-34.
147. Chen, J., V. Marechal, and A.J. Levine, *Mapping of the p53 and mdm-2 interaction domains*. Mol Cell Biol, 1993. **13**(7): p. 4107-14.
148. Momand, J., et al., *The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation*. Cell, 1992. **69**(7): p. 1237-45.
149. Oliner, J.D., et al., *Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53*. Nature, 1993. **362**(6423): p. 857-60.
150. Gu, W. and R.G. Roeder, *Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain*. Cell, 1997. **90**(4): p. 595-606.
151. Ito, A., et al., *p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2*. Embo J, 2001. **20**(6): p. 1331-40.
152. Jin, Y., et al., *MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation*. J Biol Chem, 2002. **277**(34): p. 30838-43.
153. Kobet, E., et al., *MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins*. Proc Natl Acad Sci U S A, 2000. **97**(23): p. 12547-52.
154. Sakaguchi, K., et al., *DNA damage activates p53 through a phosphorylation-acetylation cascade*. Genes Dev, 1998. **12**(18): p. 2831-41.
155. Haupt, Y., et al., *Mdm2 promotes the rapid degradation of p53*. Nature, 1997. **387**(6630): p. 296-9.
156. Kubbutat, M.H., S.N. Jones, and K.H. Vousden, *Regulation of p53 stability by Mdm2*. Nature, 1997. **387**(6630): p. 299-303.
157. Maya, R., et al., *ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage*. Genes Dev, 2001. **15**(9): p. 1067-77.
158. Mayo, L.D., J.J. Turchi, and S.J. Berberich, *Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53*. Cancer Res, 1997. **57**(22): p. 5013-6.
159. Zhou, B.P., et al., *HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation*. Nat Cell Biol, 2001. **3**(11): p. 973-82.
160. Geronikaki, A.A. and A.M. Gavalas, *Antioxidants and inflammatory disease: synthetic and natural antioxidants with anti-inflammatory activity*. Comb Chem High Throughput Screen, 2006. **9**(6): p. 425-42.
161. Thannickal, V.J. and B.L. Fanburg, *Reactive oxygen species in cell signaling*. Am J Physiol Lung Cell Mol Physiol, 2000. **279**(6): p. L1005-28.
162. Droge, W., *Free radicals in the physiological control of cell function*. Physiol Rev, 2002. **82**(1): p. 47-95.

163. Waldron, R.T. and E. Rozengurt, *Oxidative stress induces protein kinase D activation in intact cells. Involvement of Src and dependence on protein kinase C.* J Biol Chem, 2000. **275**(22): p. 17114-21.
164. Zhang, Y. and F. Chen, *Reactive oxygen species (ROS), troublemakers between nuclear factor-kappaB (NF-kappaB) and c-Jun NH(2)-terminal kinase (JNK).* Cancer Res, 2004. **64**(6): p. 1902-5.
165. Carmona-Cuenca, I., et al., *EGF blocks NADPH oxidase activation by TGF-beta in fetal rat hepatocytes, impairing oxidative stress, and cell death.* J Cell Physiol, 2006. **207**(2): p. 322-30.
166. Arakaki, N., et al., *Involvement of oxidative stress in tumor cytotoxic activity of hepatocyte growth factor/scatter factor.* J Biol Chem, 1999. **274**(19): p. 13541-6.
167. Choi, M.H., et al., *Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II.* Nature, 2005. **435**(7040): p. 347-53.
168. Colavitti, R., et al., *Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR.* J Biol Chem, 2002. **277**(5): p. 3101-8.
169. Bokoch, G.M. and U.G. Knaus, *NADPH oxidases: not just for leukocytes anymore!* Trends Biochem Sci, 2003. **28**(9): p. 502-8.
170. Czaja, M.J., *Induction and regulation of hepatocyte apoptosis by oxidative stress.* Antioxid Redox Signal, 2002. **4**(5): p. 759-67.
171. Sachsenmaier, C., et al., *Involvement of growth factor receptors in the mammalian UVC response.* Cell, 1994. **78**(6): p. 963-72.
172. Guyton, K.Z., et al., *Age-related changes in activation of mitogen-activated protein kinase cascades by oxidative stress.* J Invest Dermatol Symp Proc, 1998. **3**(1): p. 23-7.
173. Vermeulen, K., Z.N. Berneman, and D.R. Van Bockstaele, *Cell cycle and apoptosis.* Cell Prolif, 2003. **36**(3): p. 165-75.
174. Levine, A.J., *p53, the cellular gatekeeper for growth and division.* Cell, 1997. **88**(3): p. 323-31.
175. Sionov, R.V. and Y. Haupt, *The cellular response to p53: the decision between life and death.* Oncogene, 1999. **18**(45): p. 6145-57.
176. Agarwal, M.L., et al., *The p53 network.* J Biol Chem, 1998. **273**(1): p. 1-4.
177. Haupt, Y., et al., *Induction of apoptosis in HeLa cells by trans-activation-deficient p53.* Genes Dev, 1995. **9**(17): p. 2170-83.
178. Kinoshita, T., et al., *Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells.* Oncogene, 1995. **10**(11): p. 2207-12.
179. Kauffmann-Zeh, A., et al., *Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB.* Nature, 1997. **385**(6616): p. 544-8.
180. Cardone, M.H., et al., *Regulation of cell death protease caspase-9 by phosphorylation.* Science, 1998. **282**(5392): p. 1318-21.
181. Romashkova, J.A. and S.S. Makarov, *NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling.* Nature, 1999. **401**(6748): p. 86-90.
182. Macleod, K.F., Y. Hu, and T. Jacks, *Loss of Rb activates both p53-dependent and independent cell death pathways in the developing mouse nervous system.* Embo J, 1996. **15**(22): p. 6178-88.

183. Morgenbesser, S.D., et al., *p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens*. Nature, 1994. **371**(6492): p. 72-4.
184. Blattner, C., A. Sparks, and D. Lane, *Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53*. Mol Cell Biol, 1999. **19**(5): p. 3704-13.
185. Moroni, M.C., et al., *Apaf-1 is a transcriptional target for E2F and p53*. Nat Cell Biol, 2001. **3**(6): p. 552-8.
186. Fan, G., et al., *The retinoblastoma gene product inhibits TGF-beta1 induced apoptosis in primary rat hepatocytes and human HuH-7 hepatoma cells*. Oncogene, 1996. **12**(9): p. 1909-19.
187. Pucci, B., M. Kasten, and A. Giordano, *Cell cycle and apoptosis*. Neoplasia, 2000. **2**(4): p. 291-9.
188. Gil-Gomez, G., A. Berns, and H.J. Brady, *A link between cell cycle and cell death: Bax and Bcl-2 modulate Cdk2 activation during thymocyte apoptosis*. Embo J, 1998. **17**(24): p. 7209-18.
189. Hakem, A., et al., *The cyclin-dependent kinase Cdk2 regulates thymocyte apoptosis*. J Exp Med, 1999. **189**(6): p. 957-68.
190. Rubin, L.L., et al., *The molecular mechanisms of neuronal apoptosis*. Curr Opin Neurobiol, 1994. **4**(5): p. 696-702.
191. Meikrantz, W., et al., *Activation of cyclin A-dependent protein kinases during apoptosis*. Proc Natl Acad Sci U S A, 1994. **91**(9): p. 3754-8.
192. Meikrantz, W. and R. Schlegel, *Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases*. J Biol Chem, 1996. **271**(17): p. 10205-9.
193. Fang, L., et al., *p21Waf1/Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53*. Oncogene, 1999. **18**(18): p. 2789-97.
194. Lu, Y., et al., *Mutated p21(WAF1/CIP1/SDI1) lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells*. Oncogene, 1998. **16**(6): p. 705-12.
195. Hiromura, K., et al., *Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27(Kip1)*. J Clin Invest, 1999. **103**(5): p. 597-604.
196. Lloyd, R.V., et al., *p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers*. Am J Pathol, 1999. **154**(2): p. 313-23.
197. Wang, X., et al., *p27Kip1 overexpression causes apoptotic death of mammalian cells*. Oncogene, 1997. **15**(24): p. 2991-7.
198. Siegel, P.M. and J. Massague, *Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer*. Nat Rev Cancer, 2003. **3**(11): p. 807-21.
199. Lafon, C., et al., *Transforming growth factor beta 1-induced apoptosis in human ovarian carcinoma cells: protection by the antioxidant N-acetylcysteine and bcl-2*. Cell Growth Differ, 1996. **7**(8): p. 1095-104.
200. Ribeiro, A., et al., *The transforming growth factor beta(1)-inducible transcription factor TIEG1, mediates apoptosis through oxidative stress*. Hepatology, 1999. **30**(6): p. 1490-7.

201. Sanchez, A., et al., *Apoptosis induced by transforming growth factor-beta in fetal hepatocyte primary cultures: involvement of reactive oxygen intermediates*. J Biol Chem, 1996. **271**(13): p. 7416-22.
202. Ballif, B.A. and J. Blenis, *Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals*. Cell Growth Differ, 2001. **12**(8): p. 397-408.
203. Czaja, M.J., H. Liu, and Y. Wang, *Oxidant-induced hepatocyte injury from menadione is regulated by ERK and AP-1 signaling*. Hepatology, 2003. **37**(6): p. 1405-13.
204. Fang, Y., et al., *Bile acids induce mitochondrial ROS, which promote activation of receptor tyrosine kinases and signaling pathways in rat hepatocytes*. Hepatology, 2004. **40**(4): p. 961-71.
205. Guyton, K.Z., et al., *Activation of mitogen-activated protein kinase by H2O2. Role in cell survival following oxidant injury*. J Biol Chem, 1996. **271**(8): p. 4138-42.
206. Muller, J.M., et al., *Antioxidants as well as oxidants activate c-fos via Ras-dependent activation of extracellular-signal-regulated kinase 2 and Elk-1*. Eur J Biochem, 1997. **244**(1): p. 45-52.
207. Wang, X., et al., *The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival*. Biochem J, 1998. **333 (Pt 2)**: p. 291-300.
208. Rosseland, C.M., et al., *Cytoplasmic retention of peroxide-activated ERK provides survival in primary cultures of rat hepatocytes*. Hepatology, 2005. **42**(1): p. 200-7.
209. Christoffersen, T., et al., *Changes in hormone responsiveness and cyclic AMP metabolism in rat hepatocytes during primary culture and effects of supplementing the medium with insulin and dexamethasone*. Eur J Biochem, 1984. **138**(2): p. 217-26.
210. Seglen, P.O., *Preparation of isolated rat liver cells*. Methods Cell Biol, 1976. **13**: p. 29-83.
211. Fausto, N., et al., *Proto-oncogene expression and growth factors during liver regeneration*. Symp Fundam Cancer Res, 1986. **39**: p. 69-86.
212. Roth, G.S., *Age changes in signal transduction and gene expression*. Mech Ageing Dev, 1997. **98**(3): p. 231-8.
213. Sawada, N., et al., *P21waf-1/cip-1/sdi-1 is expressed at G1 phase in primary culture of hepatocytes from old rats, presumably preventing the cells from entering the S phase of the cell cycle*. Biochem Biophys Res Commun, 1996. **228**(3): p. 819-24.
214. Lindeman, B., et al., *Alteration of G1 cell-cycle protein expression and induction of p53 but not p21/waf1 by the DNA-modifying carcinogen 2-acetylaminofluorene in growth-stimulated hepatocytes in vitro*. Mol Carcinog, 1999. **24**(1): p. 36-46.
215. Ghosh, A.K., S. Bhattacharyya, and J. Varga, *The tumor suppressor p53 abrogates Smad-dependent collagen gene induction in mesenchymal cells*. J Biol Chem, 2004. **279**(46): p. 47455-63.

216. Inoue, Y., et al., *p53 May positively regulate hepatocyte proliferation in rats*. Hepatology, 2002. **36**(2): p. 336-44.
217. Tang, H.Y., et al., *Constitutive expression of the cyclin-dependent kinase inhibitor p21 is transcriptionally regulated by the tumor suppressor protein p53*. J Biol Chem, 1998. **273**(44): p. 29156-63.
218. Latonen, L., et al., *p53 and MDM2 are regulated by PI-3-kinases on multiple levels under stress induced by UV radiation and proteasome dysfunction*. Cell Signal, 2003. **15**(1): p. 95-102.
219. Bar, J., et al., *The PI3K inhibitor LY294002 prevents p53 induction by DNA damage and attenuates chemotherapy-induced apoptosis*. Cell Death Differ, 2005.
220. Weinberg, R.A., *The retinoblastoma protein and cell cycle control*. Cell, 1995. **81**(3): p. 323-30.
221. Gallant, P., A.M. Fry, and E.A. Nigg, *Protein kinases in the control of mitosis: focus on nucleocytoplasmic trafficking*. J Cell Sci Suppl, 1995. **19**: p. 21-8.
222. Grana, X. and E.P. Reddy, *Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)*. Oncogene, 1995. **11**(2): p. 211-9.
223. Pines, J., *Cyclins and cyclin-dependent kinases: a biochemical view*. Biochem J, 1995. **308 (Pt 3)**: p. 697-711.
224. Albrecht, J.H., M.Y. Hu, and F.B. Cerra, *Distinct patterns of cyclin D1 regulation in models of liver regeneration and human liver*. Biochem Biophys Res Commun, 1995. **209**(2): p. 648-55.
225. Loyer, P., et al., *Growth factor dependence of progression through G1 and S phases of adult rat hepatocytes in vitro. Evidence of a mitogen restriction point in mid-late G1*. J Biol Chem, 1996. **271**(19): p. 11484-92.
226. Fausto, N., *Liver regeneration: from laboratory to clinic*. Liver Transpl, 2001. **7**(10): p. 835-44.
227. Nelsen, C.J., et al., *Transient expression of cyclin D1 is sufficient to promote hepatocyte replication and liver growth in vivo*. Cancer Res, 2001. **61**(23): p. 8564-8.
228. Nelsen, C.J., et al., *Evidence that cyclin D1 mediates both growth and proliferation downstream of TOR in hepatocytes*. J Biol Chem, 2003. **278**(6): p. 3656-63.
229. Gonzalez, T., et al., *Inhibition of Cdk4 activity enhances translation of p27kip1 in quiescent Rb-negative cells*. J Biol Chem, 2003. **278**(15): p. 12688-95.
230. Jiang, H., H.S. Chou, and L. Zhu, *Requirement of cyclin E-Cdk2 inhibition in p16(INK4a)-mediated growth suppression*. Mol Cell Biol, 1998. **18**(9): p. 5284-90.
231. Bockstaele, L., et al., *Regulated activating Thr172 phosphorylation of cyclin-dependent kinase 4(CDK4): its relationship with cyclins and CDK "inhibitors"*. Mol Cell Biol, 2006. **26**(13): p. 5070-85.
232. Gladden, A.B. and J.A. Diehl, *Cell cycle progression without cyclin E/CDK2: breaking down the walls of dogma*. Cancer Cell, 2003. **4**(3): p. 160-2.
233. Grim, J.E. and B.E. Clurman, *Cycling without CDK2?* Trends Cell Biol, 2003. **13**(8): p. 396-9.

234. Kozar, K., et al., *Mouse development and cell proliferation in the absence of D-cyclins*. Cell, 2004. **118**(4): p. 477-91.
235. Malumbres, M., et al., *Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6*. Cell, 2004. **118**(4): p. 493-504.
236. Sanchez, I. and B.D. Dynlacht, *New insights into cyclins, CDKs, and cell cycle control*. Semin Cell Dev Biol, 2005. **16**(3): p. 311-21.
237. Sherr, C.J. and J.M. Roberts, *Living with or without cyclins and cyclin-dependent kinases*. Genes Dev, 2004. **18**(22): p. 2699-711.
238. Su, T.T. and J. Stumpff, *Promiscuity rules? The dispensability of cyclin E and Cdk2*. Sci STKE, 2004. **2004**(224): p. pe11.
239. Lundberg, A.S. and R.A. Weinberg, *Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes*. Mol Cell Biol, 1998. **18**(2): p. 753-61.
240. Nelsen, C.J., et al., *Induction of hepatocyte proliferation and liver hyperplasia by the targeted expression of cyclin E and skp2*. Oncogene, 2001. **20**(15): p. 1825-31.
241. Brunet, A., et al., *Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry*. Embo J, 1999. **18**(3): p. 664-74.
242. Formstecher, E., et al., *PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase*. Dev Cell, 2001. **1**(2): p. 239-50.
243. Robinson, M.J., et al., *A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation*. Curr Biol, 1998. **8**(21): p. 1141-50.
244. Eisenmann, K.M., et al., *Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad*. Cancer Res, 2003. **63**(23): p. 8330-7.
245. Adjei, A.A., *Blocking oncogenic Ras signaling for cancer therapy*. J Natl Cancer Inst, 2001. **93**(14): p. 1062-74.
246. Patel, T., et al., *Dysregulation of apoptosis as a mechanism of liver disease: an overview*. Semin Liver Dis, 1998. **18**(2): p. 105-14.
247. Fabregat, I., et al., *Epidermal growth factor impairs the cytochrome C/caspase-3 apoptotic pathway induced by transforming growth factor beta in rat fetal hepatocytes via a phosphoinositide 3-kinase-dependent pathway*. Hepatology, 2000. **32**(3): p. 528-35.
248. Freathy, C., et al., *Transforming growth factor-beta(1) induces apoptosis in rat FaO hepatoma cells via cytochrome c release and oligomerization of Apaf-1 to form a approximately 700-kd apoptosome caspase-processing complex*. Hepatology, 2000. **32**(4 Pt 1): p. 750-60.
249. Roberts, R.A., N.H. James, and S.C. Cosulich, *The role of protein kinase B and mitogen-activated protein kinase in epidermal growth factor and tumor necrosis factor alpha-mediated rat hepatocyte survival and apoptosis*. Hepatology, 2000. **31**(2): p. 420-7.
250. Hancock, J.F., *Ras proteins: different signals from different locations*. Nat Rev Mol Cell Biol, 2003. **4**(5): p. 373-84.

251. Gomez, G.A. and J.L. Daniotti, *H-Ras dynamically interacts with recycling endosomes in CHO-K1 cells: involvement of Rab5 and Rab11 in the trafficking of H-Ras to this pericentriolar endocytic compartment*. J Biol Chem, 2005. **280**(41): p. 34997-5010.
252. Roy, S., B. Wyse, and J.F. Hancock, *H-Ras signaling and K-Ras signaling are differentially dependent on endocytosis*. Mol Cell Biol, 2002. **22**(14): p. 5128-40.
253. Yan, J., et al., *Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase*. J Biol Chem, 1998. **273**(37): p. 24052-6.
254. Guerra, C., et al., *Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context*. Cancer Cell, 2003. **4**(2): p. 111-20.
255. Barone, M.V. and S.A. Courtneidge, *Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src*. Nature, 1995. **378**(6556): p. 509-12.
256. Toulany, M., et al., *Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway*. Radiother Oncol, 2005. **76**(2): p. 143-50.